Chapter 33
Antimitotic and Immunosuppressive Chemotherapy
Joel S. Mindel
Main Menu   Table Of Contents



Few ophthalmologists are sufficiently familiar with the actions, toxicities, and side effects of antimitotic and immunosuppressive agents to administer them without the aid of an internist trained in the treatment of neoplastic diseases. With regard to cancer chemotherapy, the treatment of metastatic tumors to the eye and orbit will largely be omitted. The reason is that the drugs chosen to treat metastases are those effective against the primary lesion without particular regard for the site(s) to which the cancer has spread.

Therapy of the most common primary tumors of the eye and orbit will be mentioned. The drugs used are discussed one-by-one. A difficulty with this approach is that currently combinations of drugs are used, often with ionizing radiation, thermotherapy, or cryotherapy. It is impossible to assess the value of each component. Further, the effectiveness of the combinations is difficult to assess because there are few, if any, controlled randomized trials. Summaries of several specific retinoblastoma studies will demonstrate some of these problems:

  1. Twenty patients with multifocal intraocular retinoblastoma were treated with eight cycles of carboplatin and vincristine at 3-week intervals over a 6-month period.1 The intravenous infusions were 560 mg/m2 carboplatin over 1 hour followed by 0.05 mg/kg vincristine. Thirty-three of 36 eyes (92%) progressed after completion of chemotherapy with a median time of 4 weeks to disease progression. In another study, 103 patients were treated with six cycles of vincristine, etoposide, and carboplatin combined with cryotherapy, thermotherapy, or plaque radiotherapy. Retinoblastoma recurrences occurred in 37% of eyes at 1 year and 51% of eyes at 3 years.2 In a third study, 51 children were treated with a combination of transpupil thermotherapy and carboplatin repeated in one to six cycles every 28 days. Subsequent enucleation or ionizing irradiation was required in 11 patients3 over a median follow-up period of 30 months.
  2. Postretinoblastoma enucleation regimens have been tested to treat or reduce the incidence of metastases.4 Forty-six patients received postenucleation chemotherapy with or without external beam radiotherapy. The chemotherapy was vincristine-doxorubicin-cyclophosphamide in 21 of these patients and vincristine-etoposide-carboplatin in 25 patients. Thirty-four patients did not receive postenucleation chemotherapy. Of the 10 patients who had metastases in the 6- to 57-month follow-up period, eight had not received postenucleation chemotherapy. In another study, four patients with noncentral nervous system spread survived their 46- to 80-month follow-up periods after the diagnosis of metastases.5 Their therapy (after the diagosis of metastases) consisted first of various combinations of vincristine-doxorubicin-cyclophosphamide-cisplatin or carboplatin-etoposide. Stem cells were then harvested after bone marrow disease was no longer detectable. The patients then received high dose chemotherapy with thiotepa (300 mg/m2 per day) and carboplatin (maximum dose 500 mg/m2 per day). The cryopreserved stem cells were infused approximately 72 hours after completion of chemotherapy and radiation therapy was given to all previous metastatic sites.

With regard to the use of these antimitotic and immunosuppressive agents in inflammations, they are usually reserved for when useful vision is threatened or corticosteroids cannot be administered. The patients must be willing to have frequent laboratory studies and accept the possibility of life-threatening bone marrow depression. Immunosuppressive agents may cause oncogenesis6,7 and can promote the growth and spread of malignancies. Andrasch and co-workers unknowingly treated a 78-year-old patient with lymphoma cells in the vitreous for “uveitis.”8,9 After many months of treatment with prednisone and chlorambucil the patient died from central nervous system (CNS) involvement.

Back to Top


Methotrexate has been used to treat retinoblastoma metastatic to the central nervous system.10 Intrathecal methotrexate, 0.25 to 0.50 mg/kg, was given every other day until no tumor cells were present in the cerebrospinal fluid. While some prolongation of life may have occurred, the treatment was not curative.

Abramson and co-workers stated that initially they used methotrexate to treat orbital rhabdomyosarcoma but ultimately preferred a combination of other drugs.11

A patient with vitreous and spinal fluid involvement by non-Hodgkin lymphoma was treated with a single course of intravenous methrotrexate 1.5 gm/m2 bolus over 1 hour followed by 300 mg/m2 per hour over 24 hours for a total of 8.4 g in the 24-hour period.12 Seven and 74 hours after initiation of treatment, the respective anterior chamber, serum, and spinal fluid levels of methrotrexate were 55.7, 219, and 2.5 micromoles/L and 1.2, 0.5 and 0.2 micromoles/L. The minimal methrotrexate tumoricidal level is 1 micromole/L. Methrotrexate normally penetrates more poorly into the eye and spinal fluid. The better penetration found here was probably the result of breakdown in the blood—brain and blood—ocular barriers because of tumor cell infiltration. Direct intravitreal injection of methrotrexate has been used to avoid the need for radiation therapy of intraocular lymphoma cells.13 Methrotrexate, 400 micrograms in 0.1 ML, was injected intravitreally.14 Twice-weekly induction injections were required for 1 or 2 months, followed by monthly injections. All 26 eyes of 16 patients were clinically clear of cells after a maximum of 12 injections. Of the 16 patients, 14 were also treated with systemic chemotherapy. In six eyes of three patients there were recurrences 12 to 24 months later. In all six of these eyes, a repeat course of intravitreal methrotrexate was effective. Adverse effects were cataract (73% incidence), corneal epitheliopathy (58% incidence), maculopathy (42% incidence), vitreous hemorrhage (8% incidence), optic atrophy (4% incidence), and sterile endophthalmitis (4% incidence).

Corticosteroid-resistant uveitis has been successfully treated with methotrexate. Wong and Hersh gave methotrexate, 25 mg/M2, to patients with pars planitis.15 Each dose was injected intravenously within a 1- to 2-minute period every 4 days for 6 weeks. All six patients improved within 3 weeks, but five of the six relapsed when treatment was discontinued. Similar improvements followed by relapses were reported in additional subjects with pars planitis16 and in subjects with sympathetic ophthalmia.16–18 A prolonged remission occurred in a patient with orbital pseudotumor.18 Lazar and co-workers, using a similar dose regimen, reported successes in uveitis patients with sarcoidosis, juvenile rheumatoid arthritis, and uveitis of unknown origin.18 A patient with presumed toxoplasmosis uveitis did not improve. Owen and Cohen treated three severe cases of Reiter's syndrome successfully by giving methotrexate, 0.3 mg/kg, 1 day every week; one of the patients could not be tapered off the drug, however.19 The progression of bilateral Mooren's ulcers was arrested using 6- to 8-week courses of intravenous methotrexate, 25 or 50 mg/wk.20,21

Toxicities were frequent. Wong reported that 47% of patients had abnormal liver studies (i.e., increased serum glutamic oxaloacetic transaminase, increased serum glutamic pyruvic transaminase, and increased sodium sulfobromophthalein [Bromsulphalein] retention).16 The enzyme elevations occurred within 72 hours of starting methotrexate and returned to normal 1 to 2 weeks after discontinuing the medication. Pneumonitis occurred in two subjects on methotrexate therapy for 11 and 22 weeks. Lazar and co-workers18 reported that of 17 patients, 13 had gastrointestinal symptoms of anorexia, nausea, or vomiting; 11 had stomatitis; 5 had alopecia; 4 had secondary infections; and 4 had reductions in their white blood cell count below 4000/mm3 or in their platelet count below 100,000/mm3. Chemical, but not symptomatic, evidence of liver disease was found in four of the 17 patients. Only one patient was without side effects. There appeared to be no correlation between the severity of side effects and the degree of ocular improvement.

Methrotrexate has been used to replace corticosteroids in treatments in which corticosteroid side effects might prevent continued therapy. For example, oral methrotrexate appeared to allow reduction of corticosteroid dosage in three patients with sarcoid-associated optic neuropathy.22 Methrotrexate, in doses less than 20 mg per week, does not appear to effect bone density.23,24 The two ocular-involving diseases in which methrotrexate has been used to reduce corticosteroid need are temporal arteritis and sarcoidosis. Two prospective studies from the same medical center, one of them masked, randomized and placebo-controlled, concluded that methrotrexate was an effective substitute that allowed reduced corticosteroid dosage when treating temporal arteritis.25,26 However, two other prospective, randomized, masked, and placebo-controlled studies, one of which was multicentered, provided evidence that methrotrexate treatment did not reduce the cumulative corticosteroid dose needed, nor did it reduce the treatment-related corticosteroid side effects in temporal arteritis.27,28 These conflicting results are difficult to resolve.

Back to Top


Fluorouracil (5-FU) is converted intracellularly to fluorodeoxyuracil monophosphate. Fluorouracil monophosphate is an inhibitor of thymidylate synthetase and, hence, of DNA synthesis. Fluorouracil is also incorporated into transcribed RNA, resulting in abnormal ribosomes and messenger RNA. The antifungal agent fluorocytosine may exert its effect by being converted to fluorouracil.

Topical chemotherapy alone, although usually not sufficient for invasive malignancies of the cornea and conjunctiva, has been used for epithelial dysplasias and noninvasive tumors. Topical 5-FU, 1% eye drops, administered four times daily for 4 weeks has successfully treated squamous cell carcinoma of the conjunctiva in seven of eight patients with mean follow-up of 27 months.29 The eighth patient required a second course of treatment. Neoplastic cells were completely replaced by normal epithelium within 3 months. One case has been reported which failed to respond to topical mitomycin C, 0.02% administered four times daily for 2 weeks but did respond to topical 5-FU, 1% administered four times daily for a total of 7 weeks; treatment had to be interrupted because of the development of a severe corneal epithelial ulcer. A limbal autograft transplant was required 24 months after the initiation of 5-FU treatment.30 However, another case has been reported which failed to fully respond to 6 months of 5-FU, 1% eye drop treatment, four times a day for 4 days a week but did respond to topical mitomycin C.31 The other six patients in this series, exhibiting epithelial dysplasia or carcinoma in situ of the conjunctiva and/or cornea, did respond to topical 5-FU. Complications of 5-FU topical treatment, besides epithelial defects, included corneal opacification and persistent erythema of the lid skin. Stenosis of the lacrimal punctum and/or ducts, which has been observed with systemic 5-FU treatment, has not been reported with topical treatment.

5-FU, 0.01% has been applied, on a sponge, to the bare sclera of 20 eyes for a 5-minute period after pterygium removal. The incidence of pterygium recurrence was higher (60%) in the 5-FU group than in the 20 control eyes (35%).32 The authors concluded that 5-FU, at this concentration, was ineffective.

Abramson and co-workers treated rhabdomyosarcoma of the orbit with fluorouracil but found other agents superior.11

Pyrimidine analogs have been investigated as treatments for ocular disorders in which nontumor cellular proliferations occur. Examples of such conditions are proliferative vitreoretinopathy and postoperative subconjunctival fibrosis. While some studies have looked at other drugs, e.g., cytosine arabinoside (Ara-C),33 the major focus has been on 5-fluorouracil.

5-FU has been injected into the anterior chamber to treat a retrocorneal downgrowth following corneal transplantation.34 Two injections of viscoclastic materials containing 0.2 mg 5-FU in the first and, when that failed to halt progression, 1.0 mg in the second, were effective. However, the graft failed and had to be replaced. This patient was aphakic. Concerns have been expressed about the effect of 5-FU on the lens in phakic subjects. An immediate marked anterior lens opacification occurred after injecting 5 mg of 5-FU adjacent to an encapsulated bleb after filtering surgery.35 The acuity fell to finger counting at one foot, but lens clarity and full acuity returned within 24 hours. A single case report claimed successful treatment of epithelial down-growth onto the corneal endothelium in an aphakic eye using two anterior chamber injections of 0.5 mg of 5-FU.36 The injections were separated by 2 weeks.

Fluorouracil mitigated proliferative vitreoretinopathy by dual action: reduced cell mitosis and reduced membrane contractility.37 Rabbits had an intraocular injection of cultured retinal pigment epithelial cells followed by intravitreal fluorouracil, 0.5 mg per day for 1 week. The incidence of retinal detachment 2 weeks after cell injection was significantly less in fluorouracil-treated eyes (6 of 14 eyes) than in control eyes (12 of 12 eyes).38 The drug also decreased proliferation of human RPE cells in vitro.39 Fluorouracil has been injected in human eyes: 10 mg intravitreally following evacuation of vitreous hemorrhage caused by neovascular proliferation. Efficacy could not be determined, because too few eyes were utilized.40 In an uncontrolled study,41 patients with advanced proliferative vitreoretinopathy were treated with surgery plus various combinations of multiple subconjunctival injections of 5-fluorouracil, 10 mg and intravitreal 5-fluorouracil, 1 mg. At 6 months 60% of the retinas remained attached, an incidence of success somewhat higher than the surgeons would have expected if fluorouracil had not been used. In a prospective, masked, randomized placebo controlled study of 174 patients, vitrectomy infusion fluid containing 5-FU, 0.2 mg/ML plus low-molecular-weight heparin 5 IU/ML, significantly reduced the incidence of postoperative proliferative vitreoretinopathy, 12.6% versus 26.4% in the group receiving placebo.42 There were no differences in the incidences of postoperative hyphemas and complication rates.

The retinal toxicity of 5-fluorouracil has been investigated in rabbit eyes.43 There was no alteration of the b-wave amplitude of the electroretinogram until vitreous cavity concentrations were maintained at 0.1 mg/ML for 1 hour. Injecting 0.5 mg of fluorouracil every 24 hours for 7 days in vitrectomized eyes reduced pigment epithelial cell mitosis but did not alter retinal histology or the electroretinogram response.44 If 1.25 mg 5-FU were injected daily for 1 week, both photoreceptor histology and electroretinogram response were markedly altered with partial recovery after 5 weeks. Little intravitreal 5-fluorouracil reached the aqueous humor within 4 hours of injection if the lens were entirely intact (0.6% drug recovery) or if only the anterior lens capsule were intact (10% drug recovery).45

5-Fluorouracil has been used in glaucoma filtration surgery to prevent failure from postoperative fibrosis. Proliferation of cultures of rabbit conjunctival fibroblasts could be inhibited 50% at concentrations of 0.2 μg/ML.46 Single subconjunctival injections of 5 mg fluorouracil maintained rabbit corneal, conjunctival, and scleral drug levels above this 50% inhibitory level for at least 24 hours.47 Eye drops of 5-fluorouracil appeared considerably more toxic to rabbit corneal epithelium than were subconjunctival injections.48,49

Several small nonrandomized50,51 and randomized52 studies of patients suggested that postoperative subconjunctival injections of 5-fluorouracil improved the results of filtering surgery except in the presence of neovascular glaucoma.53 The major complications of therapy were conjunctival wound leaks, corneal epithelial defects, and suprachoroidal hemorrhages.54 A larger randomized study55 of 213 glaucoma patients who were followed-up for 1 year after receiving subconjunctival 5-fluorouracil, 5 mg in 0.5 ML, documented the therapeutic efficacy of the drug. Treatment was begun on the day after surgery in 105 eyes and consisted of two injections daily on days 1 to 7 and one injection daily on days 8 to 14. The 108 control eyes did not receive placebo injections. At 1 year, 27% of the treated group and 50% of the control group had intraocular pressures of 21 mm Hg or greater or had to have additional filtration surgery. Subconjunctival injections, even when begun 3 to 15 days postoperatively if clinical signs suggested early bleb failure, appeared effective.56 The 213 patients in the large randomized study were followed-up. In a subsequent report of the 5-year follow-up data, 51% of the 5-FU group and 74% of the control group were classified as having failed; this difference was significant (p<0.001).57 A retrospective study came to the same conclusion: 5-FU increased the success rate but there was a progressive loss of pressure control with time.58 Loss of control in eyes considered successfully treated at 1 year was 39% at 5 years, 56% at 10 years, and 59% at 14 years.

Lower total doses of injected 5-FU have been tested post-trabeculectomy, e.g., three doses of 5 mg each. These provided no significant benefit to the intraocular pressure reduction at 1 year.59

An alternative technique has used a soaked pledget to apply 5-FU to the scleral bed during trabeculectomy surgery.60–62 Soaking solutions of 25 to 50 mg 5-FU per ML have been used. Appling the pledget for 5 minutes appeared to be effective but none of the studies had control groups and supplementary conjunctival 5-FU injections were often given postoperatively. Side effects, consisting of conjunctival wound leaks, epithelial defects, hypotony, choroidal effusions/hemorrhages, and hyphemas/vitreous hemorrhages, seemed to occur less if the subconjunctival injections could be avoided. A masked, randomized trial in 103 patients compared the primary trabeculectomy results of applying topical 5-FU, 50 mg/ML on a pledget for 5 minutes, to topical mitomycin C, 0.2 mg/ML on a pledget for 2 minutes.63 The results were statistically similar at 12 months posttrabeculectomy with 94% of 5-FU eyes and 80% of mitomycin C eyes having pressures of 21 mm Hg or less.



Wirostko and Halbert produced uveitis in rabbits by injecting bovine serum albumin intravitreally.64 A marked inflammation occurred in 5 to 9 days. Serum antibodies to albumin were detectable within 9 days. When mercaptopurine, 5 mg/kg per day, was given intramuscularly for 14 days beginning with the intravitreal injection, there was a marked reduction in the uveitis. During treatment, antibody levels to bovine serum albumin were decreased. In 26% of the rabbits, antibody levels were undetectable. However, after discontinuing therapy, a slow steady increase in antibody levels occurred.

Mercaptopurine has been used, in daily doses of 2 to 2.7 mg/kg for 8 to 35 days, to treat pars planitis, idiopathic uveitis, sympathetic ophthalmitis, and acute histoplasmosis chorioretinitis.65 Most, but not all, patients had improvement of their acuity or visual fields and/or reduction in cell, flare, or lesion size. Relapses commonly occurred when therapy was discontinued. Several patients received two courses of therapy.


This drug is a derivative of mercaptopurine and slowly releases free mercaptopurine after it is administered. As a result, toxicity is reduced.

Rabbits66–68 had delayed healing of penetrating corneal incisions when given azathioprine, 48 mg/kg, every other day beginning at the time of wounding and continued through postoperative day 10. The ability of azathioprine to suppress corneal heterograft reactions was tested in three groups of 15 rabbits each. All grafts were clear 42 days after transplantation if intramuscular azathioprine, 48 mg/kg, were given every other day from the time of surgery through postoperative day 10 and if topical methylprednisolone, 0.1% ointment, twice per day, were applied beginning on day 10. Twelve of 15 grafts remained clear on day 42 after using the corticosteroid ointment alone beginning on postoperative day 11. Only one of 12 grafts remained clear when azathioprine alone was given for 10 days. In another group of rabbits, topical azathioprine, 0.1% or 1% in petrolatum or water-soluble ointment, applied three times per day, failed to prevent rejection. Cleasby and co-workers found that azathioprine, 20 mg/kg per day, delayed rabbit graft rejections, but that 10 mg/kg did not.69 However, maintenance on 5 mg/kg per day azathioprine plus 0.5 mg/kg per day prednisolone was effective.

Azathioprine has been given to patients whose ages ranged from 3 to 68 years with Graves disease and a number of other inflammatory conditions. Burrow and co-workers treated five patients with Graves disease who had positive assays for long-acting thyroid stimulating protein (LATS).70 Azathioprine, 2 mg/kg per day, was administered for up to 36 weeks. There was no improvement (i.e., no decrease in exophthalmos or increase in ocular movements) despite evidence of suppression of primary and secondary humoral immune responses and of delayed hypersensitivity. The chemosis and conjunctival injection of one patient was somewhat reduced by the therapy. Another study, using a matched control, confirmed that a 1-year treatment course of azathioprine was ineffective in altering thyroid ophthalmopathy.71

A 2-year randomized, placebo-controlled masked study demonstrated that azathioprine, 2.5 mg/kg per day reduced the incidence of uveitis and hypopyon in patients with Behçet's syndrome.72 Scleritis and uveitis from rheumatoid arthritis, Wegener's granulomatosis, herpes zoster, Vogt-Koyanagi-Harada syndrome, pars planitis, and sympathetic ophthalmia have been successfully treated with combinations of azathioprine and systemic corticosteroids.73–77 Not all patients responded. Initial doses ranged from 1.5 to 3.0 mg/kg per day azathioprine followed by maintenance doses of 1.0 to 1.5 mg/kg per day. Some investigators did not administer the drug on a body weight basis but instead used fixed doses of 50 to 200 mg/day. Exacerbations of disease frequently occurred when therapy was tapered.

In those studies in which azathioprine, cyclophosphamide, and chlorambucil were used, chlorambucil and especially cyclophosphamide were considered superior because side effects and toxicity were less frequent.77 Andrasch and co-workers stated that in 10 of 22 patients begun on azathioprine, adverse side effects, or poor therapeutic responses necessitated a change to chlorambucil.9 Adverse effects included skin rash, arthralgia, fever, leukopenia, thrombocytopenia, and gastrointestinal symptoms. Mild to moderate leukopenia occurred in 10 of 20 patients receiving 1.5 to 3.0 mg/kg per day azathioprine.73 This was adequately treated by decreasing or discontinuing the drug. These authors performed a complete blood cell count, including a platelet count, twice per week. In a study demonstrating the effectiveness of immunosuppressive therapy in cicatricial ocular pemphigoid, five of 18 patients initially treated with cyclophosphamide had azathioprine either substituted or added to their regimen78 because of cyclophosphamide intolerance or ineffectiveness. However, azathioprine was not tolerated or was ineffective in four of them.



Hahnenberger injected 100 μg vinblastine into the vitreous cavities of cats.79 Hypopyons developed and the corneas became inflamed and opaque. Corneal sensation disappeared after the third day and was not fully recovered 1 month later. The irides appeared to function normally 1 month postinjection but were supersensitive to pilocarpine and norepinephrine injected intramuscularly in doses that did not cause untreated eyes to respond.

Bhattacherjee and Eakins found that topical vinblastine, 2 μg to 5 μg, lowered rabbit intraocular pressure for more than 24 hours without causing irritation or pupil constriction.80

Twenty patients enucleated for primary ocular melanoma but without evidence of metastases were treated prophylactically with a five drug combination chemotherapy.81 Nineteen were treated within 1 month after enucleation and one patient was treated 1 year after enucleation. Intravenous vinblastine, 5 mg/m2 body surface, was one of the drugs used. With a median follow-up of 6 years, 17 patients, i.e., 89%, were disease-free, which was considerably better than the 38% to 65% incidence of disease-free patients at 5 years reported in the literature.

Vincristine has been used to treat retinoblastoma82 and orbital rhabdomyosarcoma11 in combination with cyclophosphamide. Vincristine, 2 mg/m2, was given intravenously once each week for 12 weeks beginning on the day that the diagnosis of rhabdomyosarcoma was confirmed pathologically. The maximum single dose was 2 mg. Too few patients were treated to evaluate whether chemotherapy plus irradiation was superior to irradiation alone. When the disease was confined to the orbit, the 3-year survival rate was 66% from irradiation alone and 91% from combination therapy. When the sinuses were invaded, the survival rate after irradiation was 44% whereas that from irradiation plus chemotherapy was 50%.



Colchicine interferes with mitosis and microtubular function. Colchicine does not inhibit actin filament formation and, therefore, does not affect rat corneal epithelial cell migration during wound healing.83–84 However, its use has been associated with nonhealing corneal ulcers in a small number of patients.85 Doses of 10 or 100 μg were injected intravitreally into pigeons. Transmission along the optic nerve was not affected, but there was reduced synaptic transmission at the ganglion cell axon terminals. This was interpreted as evidence of colchicine interference with axonal transport.86

Beebe and co-workers reported that colchicine, 10-10 M, added to tissue cultures, prevented elongation and increased volume of chicken lens cells.87 This concentration was too low to affect microtubular function, suggesting that colchicine had additional sites of action.

Hahnenberger injected 100 or 300 μg colchicine unilaterally into the vitreous cavities of cats.79 Corneal sensation disappeared after the third day, and 1 month later it had not fully recovered. The consensual light responses of the injected and control eyes were temporarily abolished. These results indicate that colchicine causes dysfunction in both sensory and motor neurons.

Topical application of 5 μg of colchicine caused a 2-mm Hg reduction in rabbit intraocular pressure 24 hours later without evidence of irritation. Maximum hypotension occurred with 50 μg colchicine. The pressure was reduced 10 mm Hg at 24 hours. However, at this dose, conjunctival irritation and miosis were present. The decrease in intraocular pressure was slow in onset. It began 8 hours after administration and was at maximum at 24 hours. Intravenous colchicine, 1 mg/kg, did not lower intraocular pressure. Lumicolchicine, an inactive isomer of colchicine, was ineffective topically.80

Mizushima and co-workers treated 157 patients with ocular involvement from Behçet's disease with colchicine.88 Most received 0.5 mg twice per day for more than 1 year. Doses ranged from 0.5 to 1.5 mg/day. Colchicine was stated to be far more effective than indomethacin or flufenamic acid. Two-thirds of patients had a reduction of 50% or more in the number of ocular attacks compared with the preceding year. Of the one-third of patients who did not respond, 7% had more attacks than the preceding year. Side effects associated with therapy were gastrointestinal symptoms (nausea, gastritis, and diarrhea), oligospermia, amenorrhea, hair loss, and malaise.

Hijikata and Masuda divided 91 patients with Behçet's disease into four therapy groups89: group 1 received only cyclophosphamide, 50 to 100 mg/ day; group 2 received only colchicine, 0.5 to 1.0 mg/day; group 3 received a combination of cyclophosphamide, 50 mg/day, plus colchicine, 0.5 mg/day; and group 4 received various combinations of systemic corticosteroids, nonsteroidal antiinflammatory drugs, antibiotics, and desensitization agents. The average length of treatment for these groups ranged from 1.7 to 2.2 years. The results are difficult to interpret because certain patients were excluded from the analysis (e.g., those with severe cataracts and glaucoma) and because some patients were on different regimens at different times. The authors interpreted their data as indicating therapy with colchicine and/or cyclophosphamide (groups 1 to 3) was superior to the other forms of treatment (group 4) in preventing deterioration of acuity and in reducing the frequency of attacks.


Nitrogen Mustards

Mechlorethamine is unstable in water. Therefore, once in solution, it must be injected without delay. Chlorambucil and cyclophosphamide are more stable and can be given orally. Cyclophosphamide is the most widely used of the nitrogen mustards. It is a prodrug and must be hydroxylated by cytochromes to become effective. The ultimate antitumor metabolite is believed to be phosphoramide mustard, but this is a subject of controversy.90 Unlike the other nitrogen mustards, cyclophosphamide does not cause severe central nervous system stimulation. Therefore, there is less nausea and vomiting, and convulsions, paralysis and cholinomimetic side effects do not occur.


McCarthy produced an anterior uveitis by injecting rabbits with live tubercle bacilli.91 The inflammation was partially inhibited if mechlorethamine, 8 to 16 mg, were given intravenously over the 10- to 12-day period after inoculation. This suggested the drug had a bacteriostatic effect.

Jampol and co-workers treated a single patient with corticosteroid-resistant rheumatoid sclerouveitis with a total dose 0.4 mg/kg mechlorethamine given over a period of 3 days.92 This patient could then be controlled with steroids for several months.


Abramson and co-workers initially used chlorambucil, in combination with radiation, to treat orbital rhabdomyosarcoma.11 They subsequently preferred using cyclophosphamide and vincristine.

Chlorambucil has been used successfully to control Behçet's disease, rheumatoid scleritis and uveitis, orbital pseudotumor, sympathetic ophthalmitis, Vogt-Koyanagi-Harada syndrome, pars planitis, herpes zoster uveitis, and uveitis of unknown origin.93–100 Not all patients responded, and exacerbations were common when medication was tapered. Initial oral doses ranged from 0.1 to 0.2 mg/kg, or fixed doses of 5 to 24 mg/day were given in divided doses after meals. Godfrey and co-workers used an initial dose of 2 mg/day to determine if idiosyncratic sensitivity was present.95 Doses were then increased 2 mg/day each week, with as much as 22 mg/day being given. Chlorambucil was almost always used in conjunction with systemic corticosteroids. A therapeutic response was evident after a mean period of 3.5 weeks using doses of chlorambucil of 6 to 8 mg/day; maximum improvement occurred after a mean period of 4.3 months. When tapering of medications was begun, corticosteroids were usually discontinued first. The most common toxicity was a fall in the white blood cell count or platelet count. While some bone marrow depression was common (e.g., Godfrey and co-workers95 found evidence of it in 28 of 31 patients), it was unusual for it to require cessation of treatment. Gastrointestinal symptoms, such as anorexia, nausea, burning, and diarrhea, and skin rashes were also relatively common.

The greatest success has been in the treatment of Behçet's disease. Mamo and Azzam controlled all 10 of their patients using chlorambucil for up to 17 months.93 In all but one patient, topical and systemic corticosteroids could be discontinued approximately 2 weeks after starting chlorambucil. Abdalla and Bahgat reported favorable results in seven patients with Behçet's disease treated with chlorambucil and systemic corticosteroids.94 Two patients had chlorambucil discontinued for 3 weeks because their white blood cell counts fell below 3500/mm3. Godfrey and co-workers,95 Dining and Perkins,96 and Mamo97 reported control in a total of 22 of 23 patients with Behçet's disease. Tricoulis reported successes in five patients, two of whom had been unsuccessfully treated with azathioprine.98

In sympathetic ophthalmitis patients, chlorambucil doses were increased relatively rapidly over a short period until bone marrow suppression occurred. The initial dose of chlorambucil was 2 mg/day orally and was increased by 2 mg/day each week. Control of the intraocular inflammation appeared to coincide with bone marrow suppression. The drug was then discontinued and the disease could be controlled with topical steroids alone.101

The enthusiasm for chlorambucil has been tempered by the demonstration that its use produced testicular atrophy102 and leukemia.103 In patients with polycythemia vera, the incidence of acute leukemia was 13-times greater in those treated with chlorambucil than in those treated with phlebotomy alone. Use of a low total dose of chlorambucil may avert these problems. Sperm counts remain in the normal range if less than 6.1 mg/kg is given104 and acute leukemia becomes rare if less than 1 g is given.105 This latter information in particular has altered the way in which the drug is prescribed.


Abramson and co-workers reported that treatment of orbital rhabdomyosarcoma with either irradiation alone (25 patients) or irradiation plus chemotherapy (33 patients) was effective.11 The overall mean survival rate, approximately 70% in patients followed-up an average of 5.2 years, was superior to that from surgical therapy alone. Initially chlorambucil, 5-fluorouracil, and methotrexate were used. Subsequently, the preferred chemotherapy regimen consisted of cyclophosphamide and vincristine, with dactinomycin added at the conclusion of radiotherapy. Cyclophosphamide, 10 mg/kg per day, was given intravenously beginning the day the pathologic diagnosis was made and was continued for 5 days. During week 13 of therapy, cyclophosphamide, 10 mg/kg per day, was given orally for 7 days. From weeks 21 to 104, cyclophosphamide, 2.5 mg/kg per day, was given orally. Vincristine was given intravenously beginning the day the pathologic diagnosis was made and was continued for 12 weeks. Dactinomycin, 0.015 mg/kg per day, was given intravenously for 5 days of each week during weeks 18, 30, 42, and 54. When the sinuses were invaded, the survival rate after irradiation plus chemotherapy was approximately the same as that following irradiation alone, being approximately 50%. When the disease was confined to the orbit only, the 3-year survival rate after irradiation alone (66%) was less than that after irradiation plus chemotherapy (91%). However, too few patients (17) were in this category of the study to permit a statistical analysis for significance.

Oral and intravenous cyclophosphamide has been used in the treatment of retinoblastoma but without apparent value.10,82,106 Wolff and co-workers used intrathecal cyclophosphamide, 4 to 8 mg/ kg every other day for 8 days, to treat central nervous system spread of the disease; some slight prolongation of life may have occurred.10 Malik and co-workers107 also reported only a limited response of CNS retinoblastoma to a combination of intravenous cyclophosphamide and vincristine.

Because of evidence that the ophthalmopathy of Graves disease was caused by an immune system abnormality, cyclophosphamide therapy was attempted by Bigos and co-workers in three patients with this disease.108 Varying degrees of success occurred in all three. Patient 1 was treated for a coexisting pelvic tumor with intravenous cyclophosphamide, 700 mg/mo, and doxorubicin, 500 mg/mo. Both were administered for 1 year. After 2 months of treatment, the patient's diplopia, present for 5 years, and foreign body sensation disappeared. Proptosis was unaffected. When the drugs were discontinued, there was no recurrence of symptoms and the patient remained stable during 22 months of follow-up. Patient 2 was placed on cyclophosphamide, 150 mg/day, and primary gaze diplopia, but not lateral gaze diplopia, resolved. Cyclophosphamide was discontinued after 15 months of treatment. After 28 months of follow-up, the primary position diplopia had not returned. Proptosis was unaffected by therapy. Patient 3 had 20/80 (6/24)* vision and disc edema caused by thyroid ophthalmopathy. Within 3 months of beginning oral therapy with cyclophosphamide, 8.5 mg/ day, the disc edema disappeared and the vision improved to 20/20 (6/6). After 2 years of follow-up, there was no return of signs or symptoms. Just as in the other two patients, proptosis was unaffected.

*Metric equivalent given in parenthesis following Snellen notation.

Cyclophosphamide has been successfully used in intraocular inflammations. Animal studies suggested that it preferentially reduced the number of B lymphocytes.109 Oh injected herpes simplex type 1 virus into rabbit eyes to produce uveitis.110,111 Intramuscular cyclophosphamide, 80 mg, every other day, did not alter the inflammation found during the first 6 days. Thereafter, the inflammation was somewhat suppressed but virus growth was more abundant. Circulating antibody levels were decreased. Similar doses of cyclophosphamide, begun 8 days before a secondary herpes simplex uveitis, had little effect. Presumably the secondary immune response was more resistant to suppression.

Patients with uveitis have been treated with daily oral doses of 25 to 250 mg cyclophosphamide.112,113 The 250-mg dose, calculated on a weight basis, was 5 mg/kg per day. Intravenous therapy with 1 g/m2 per week has also been administered.16 Corticosteroids usually were given until the signs and symptoms remitted.92,114,115 Hijikata and Ma-suda used cyclophosphamide plus colchicine.89 Duration of therapy, using tapering medications, was for a minimum of 3 weeks. Hemorrhagic cystitis caused discontinuation of therapy in a patient treated 2 years with 150 mg/day. Other toxicities included bone marrow suppression, nausea, diarrhea, hemorrhagic gastritis, alopecia, sterility, and cardiac toxicity. Kende and co-workers reported temporary blurring of vision in 17% of children given large doses of cyclophosphamide.116 Blurring began in minutes to 24 hours after administration of the drug, could occur at any time during the course of therapy, and lasted less than 1 hour or up to 2 weeks. Continuation of therapy did not cause a recurrence.

Successful control has been reported for sympathetic ophthalmitis, orbital pseudotumor, orbital vasculitis, corneal transplant rejection, pars planitis, ocular Behçet's disease, rheumatoid sclerouveitis, uveitis associated with polyarteritis nodosa and systemic lupus erythematosus, ocular Wegener's granulomatosis, and pyoderma gan-grenosum scleritis.16,21,77,89,92,112–115,117 Not all cases responded. Those that did respond did so after days to weeks of therapy. Buckley and Gills treated five patients with presumed toxoplasmosis retinitis.112 The response was variable. In two patients, the inflammation decreased. Permanent remissions have been reported in patients with Wegener's granulomatosis.92 The response of ocular cicatricial pemphigoid to cyclophosphamide was variable and difficult to assess because the disease itself did not always progress.118 However, the overall results seemed better in the treated groups. Chronic therapy with cyclophosphamide has been associated with chromosome damage,119 carcinoma of the bladder,120 and leukemia.121 In rheumatoid arthritis patients in whom necrotizing scleritis or keratitis developed, cytotoxic immunosuppressive therapy not only improved the ocular outcome but also reduced the lethal effects of the systemic vasculitis.122 Nine of 17 patients who were managed without immunosuppressive therapy died. Only one of 11 patients treated with cyclophosphamide died.


Ifsomide is a nitrogen mustard-type of alkylating agent that must be metabolically activated. Its cytotoxic activity is primarily because of cross-linking DNA and RNA. The drug is administered parentally. Activation and subsequent degradation of ifosfamide take place in the liver. Excretion is largely in the urine. The larger the dose, the more likely the drug will be excreted in the urine unmetabolized. The drug is renal and hepatotoxic.

Ifosfamide has been used with combination irradiation, vincristine and dactinomycin or etoposide to treat rhabdomyosarcoma of the orbit.



Triethylenemelamine (TEM) has been used to treat retinoblastomas with unfavorable prognoses, often in combination with radiotherapy. TEM was injected, under direct observation, into the internal carotid artery. Krementz and co-workers gave 0.03 mg/kg per day for 7 to 10 days.123 Ellsworth injected a single dose of 0.08 to 0.1 mg/kg.124 Bishop and Madison occasionally gave a second injection of 0.08 to 0.1 mg/kg approximately 6 to 8 weeks after the first.125 It is difficult to evaluate efficacy. The largest series was that of Reese and Ellsworth.126,127 Between 1960 and 1965, 116 patients with poor prognoses were treated with TEM and radiotherapy.124 There was an average 5-year follow-up. The 5-year cure rate in patients with multiple tumors, some of which were larger than 10 disc diameters, or with tumors anterior to the ora serrata, was 69%. That in patients with tumors involving more than half the retina or with vitreous seeding was 34%. That in patients with orbital involvement was 30%. The visual acuities in these survivors were not given.


Thiotepa (triethylenethiophosphoramide) 1% in sesame or olive oil temporarily inhibited rabbit corneal vascularization when applied three or four times a day.128,129 At a 0.05% concentration in Ringer's solution, it has been used topically in humans to prevent recurrence of pterygia. At this concentration, Liddy and Morgan stated that the drug is stable for more than 15 days when stored at 3°C.130 Thiotepa is applied topically after the removal of the pterygium in the hope that it will prevent the corneal neovascularization associated with recurrences. Olander and co-workers, after a thorough review of the literature, found it impossible to compare the prophylactic value of thiotepa with that of β-irradiation.131 Different authors have not been uniform in their frequency of treatments; control groups are often inadequate or lacking altogether.

Thiotepa 0.05%, with and without topical corticosteroids, has been applied every 3 hours for 3 to 8 weeks after “bare sclera” removal of pterygia. Treatment began 1 to 7 days after surgery.130,132,133 Follow-up periods in general ranged from 2 to 3 years. Recurrence rates in the treated eyes ranged from 6% to 8%. In a control group of 48 patients, Kleis and Guillermo reported a 31% recurrence rate.

Concentrations as high as 0.2% have been used without signs of toxicity.134 However, the 0.05% solution has occasionally caused depigmentation of the skin and poliosis around the treated eye.135 These may be late occurrences (e.g., 8 months after discontinuing therapy).136 Joselson and Muller reported that 85% of 46 patients treated with 0.05% thiotepa had a steroid-resistant, extended postoperative hyperemia; one patient had conjunctival hypertrophy 3 weeks after the drug was discontinued.137 In guinea pigs, lid and lash toxicity occurred when 1% thiotepa was given every 4 hours.138 In rats, 0.22% thiotepa, eight times per day for 6 weeks, produced both cataracts and corneal vascularization.139 Berkow and co-workers attempted to treat a corneal graft reaction with 1% thiotepa in peanut oil, twice per day for 23 days.140 Progressive depigmentation of the lids occurred in this black patient over the next 6 months. When the other eye was grafted, 1% thiotepa was used twice a day for only 3 days. Again, the skin became depigmented. The grafts remained clear bilaterally, but there was no return of skin pigment during the 5-year follow-up. Because a similar depigmentation occurred when thiotepa was placed on the patient's forearm, as a patch test, these authors considered the response to be idiosyncratic.

Back to Top


Rabbits with epitheliomas implanted bilaterally into their anterior chambers were treated with unilateral carmustine (BCNU) or dacarbazine (DTIC).141 The drugs were injected either subconjunctivally or into the anterior chamber every 3 days for 18 days. Both drugs, given in either location, were successful in delaying tumor growth. Carmustine, unlike dacarbazine, is lipophilic and when given intravenously penetrated the eye in sufficient quantities to be effective. The doses used were dacarbazine, 0.6 mg per anterior chamber injection and 1.5 mg per subconjunctival injection; carmustine, 0.2 mg per anterior chamber injection, 0.5 mg per subconjunctival injection, 2.25 mg/kg, intravenously, four times in 12 days when used in combination therapy, and 3.13 mg/kg, intravenously, four times in 12 days when used alone.

Carmustine has been injected into the carotid arteries of patients with brain tumors. A complication was ipsilateral ischemic ocular disease. This could be avoided by advancing the catheter tip beyond the take-off of the ophthalmic artery before injecting the drug.142–144

Dacarbazine could be injected intravitreally into rabbit eyes in 1-mg doses, and the injections repeated four times, without ocular damage. However, injections of 2 mg caused vitreous hemorrhage beginning with the second injection and retinal damage beginning with the third injection.145

Dacarbazine has been used to treat malignant melanoma elsewhere in the body. Intravitreal injections would be of questionable value in primary ocular malignant melanoma because the drug, in passing through the retina to reach the tumor in the choroid, might damage the neurosensory epithelium. Wilczek used 14C-labeled dacarbazine to evaluate rabbit and monkey eye penetration.146 In rabbits, 0.5 mg was injected intravenously or 0.125 mg was injected retrobulbarly. Monkey eyes received 1.0 to 7.5 mg of unlabeled dacarbazine retrobulbarly, twice per day for a total of four injections (i.e., a total of 4 to 30 mg). Retrobulbar injection was superior, using these doses, to intravenous therapy. Maximum concentrations occurred shortly after injection. Although those monkey eyes receiving retrobulbar injections of 1 to 2.5 mg showed no gross or histopathologic changes 2 weeks after the four injections, those eyes with injections of 5 mg and higher did develop orbital inflammation, retinitis, and uveitis.

Back to Top




Dactinomycin (actinomycin D, Cosmegen) has been used in combination therapy of metastatic retinoblastoma. Prolongation of life resulted but cure did not. Wolff and co-workers treated seven patients in whom the longest posttreatment survival was 48 months.10 Patients initially received cyclophosphamide followed by 7 days of combination therapy: dactinomycin, 75 μg/kg per day intravenous (IV) in divided doses; methotrexate, 2.5 mg/day orally; and cyclophosphamide, 5 mg/kg per day IV.

Abramson and co-workers used dactinomycin at the conclusion of radiotherapy for orbital rhabdomyosarcoma.11 Dactinomycin 0.075 mg/kg per week was given intravenously in divided doses every 12 weeks until a total dose of 0.3 mg/kg had been given.


Tan treated 1 patient with retinoblastoma and 14 patients with rhabdomyosarcoma using doxorubicin (adriablastina, Adriamycin).147 Children received 0.5 mg/kg per day for a total dose of 2 to 4 mg/ kg. Adults received 0.4 mg/kg per day for 3 days, rest for 4 days, and repeated administration, for a total dose of 2.5 mg/kg. Doxorubicin was administered intravenously as a 2-mg/ML solution in normal saline. Each dose was injected during a 2- to 3-minute period. Repeat courses were tolerated 3 to 4 weeks later in children. Adults were maintained on a weekly dose of 0.4 mg/kg.

The main toxicity was bone marrow depression: leukopenia and thrombocytopenia developed in 64% of children at an average total dose of 3 mg/kg. Alopecia, oral ulcers, fever, gastrointestinal symptoms of nausea and vomiting, and cardiac myopathy occurred.

Bigos and co-workers found that a patient with Graves disease and endocrine ophthalmopathy had resolution of his diplopia and ocular irritation, but not his proptosis, when treated with chemotherapy for a pelvic tumor.108 The patient received, for 1 year, doxorubicin, 500 mg/mo, intravenously, and cyclophosphamide, 700 mg/mo, intravenously. When therapy was discontinued, the patient remained stable, with follow-up being 22 months.

Systemic doxorubicin, in combination with cisplatin, has been used to treat basal cell and squamous cell carcinomas of the lids148 in patients who refused surgery or in whom surgery was contraindicated. The responses to therapy were excellent, but treatment efficacy was attributed primarily to the cisplatin. Intravenous doxorubicin with intracarotid cisplatin have been radiographically shown to reduce tumor size in adenocarcinoma of the lacrimal gland before orbital exenteration.149

Doxorubicin injections have been used to destroy striated muscle, i.e., produce a chemomyectomy, in patients with blepharospasm and hemifacial spasm.150 Symptomatic relief was achieved in nine of 18 blepharospasm patients and five of six hemifacial spasm patients. Bupivacaine was injected into each eyelid followed by 2 ML of doxorubicin 0.5 mg/ML given in 0.1-ML to 0.2-ML doses. Injections were repeated at intervals of 10 or more weeks until relief was achieved or the patient no longer wished to continue. However, local complications were frequent and included a skin ulcer, ectropion, entropion, redundant edematous conjunctiva, skin hyperpigmentation, and diplopia.

Mitomycin C

Mitomycin C is an antimitotic antibiotic that inhibits DNA synthesis. It requires enzymatic activation before generating DNA-alkylating moieties. Multiple enzymes are capable of this bioreduction activation.151 One of the enzymes, NAD(P)H:quinone oxidoreductase (NQ01) has been identified in normal, dysplastic and neoplastic conjunctival and corneal epithelial cells, in fibroblasts, in all retinal layers, and in optic nerve fascicles and arachnoid; the staining is minimal in photoreceptor outer segments and optic nerve pia and dura.152 Variations in the activities of the activating enzymes of different individuals may partially explain the differences found in the effectiveness and toxicity of mitomycin C.

Mitomycin C has been used topically after surgical removal of pterygia to prevent recurrences. Hayasaki and co-workers153 studied 99 eyes of 80 patients. All had surgical removal of their primary pterygia and postoperative application of topical corticosteroids and antibiotics. Mitomycin C, 0.02% in 0.9% NaCl, twice per day for the first 5 postoperative days, significantly reduced the recurrence of pterygia (7% in 29 eyes). The 31 eyes not receiving mitomycin C had a 32% recurrence rate. Reduced recurrence rates, but not superior to that of the 0.02% solution of mitomycin C, were achieved by 2000-cGy radiation (15%) and mitomycin C, 0.04%, three times per day for 1 week (11%). However, intraoperative application of 0.04% mitomycin C was found significantly more effective than 2160 cGy radiation.154 Singh and co-workers,155 using 0.04% and 0.1% solutions of mitomycin after pterygium surgery, also found the drug effective. However, the 1% solution caused some epithelial breakdown, irritation and lacrimation. Mitomycin C 0.02%, applied for 5 minutes on a sponge, and leaving the sclera bare provided a significantly lower recurrence rate, 4%, than removal using only a bare sclera, 46.7%.156 Using a conjunctival autograph was just as effective as drops of 0.02% mitomycin C, twice daily for 5 days in preventing recurrence.157 Applying mitomycin C intraoperatively seems to be as effective as using drops postoperatively.158,159

In cases of recurrent pterygia, treatment after tumor excision with either a conjunctival autograft or a sponge containing 0.02% mitomycin C for 3 minutes, provided similar recurrence rates.160

Intraoperative application and postoperative eye drops of mitomycin C after pterygium removal have been associated with severe scleral melting.161–163

Topical mitomycin C, 0.02% and 0.04%, four times daily for 7 to 28 days has been used successfully to treat corneal-conjunctival intraepithelial neoplasia and partially excised conjunctival squamous cell carcinoma. Multiple retreatments are often required and, even then, some patients had regrowth.164–167

Topical mitomycin drops have been used to treat acquired conjunctival melanosis and conjunctival melanomas.168–170 Multiple courses may be required. As expected, melanosis tended to respond better than melanomas; nodular melanomas were resistant to therapy. Secondary conjunctival epithelial microscopic changes after the topical use of mitomycin C for acquired conjunctival malanosis include nuclear enlargement and chromatin smudging-hyperchromasia;171 these superficial changes should not be confused with recurrence of atypical melanocytes but could be confused with recurrence of intraepithelial neoplasia.

The success rate of dacryocystorhinostomy is high, approximately 90%. Application of 0.02% mitomycin C to the osteotomy site for 30 minutes has resulted in larger openings and an even higher success rate.172 Simply probing the nasolacrimal duct and then irrigating with three applications of 1 ML 0.02% mitomycin successfully treated 25% of patients with epiphora; another 47% had had moderate relief.173

While drops of mitomycin C have not been effective in treating subepithelial fibrosis occurring after refractive corneal surgery, single 2-minute sponge applications of 0.02% to the debrided surface have controlled this condition.174 Other uses of mitomycin C have been to control progressive conjunctival scarring in ocular pemphigoid by using subconjunctival injections and to prevent the reformation of lysed conjunctival adhesions by using a topical 0.04% solution for 3 to 5 minutes.175,176

Glaucoma filtration surgery failures are often due to post-operative scarring. Mitomycin C has been effective in increasing the success rate. Part of its efficacy may be caused by reduced fibroblast migration. Cultures of human Tenon's capsule fibroblasts showed significantly reduced motility for up to 48 days after 5 minutes of exposure to mitomycin C; 5-fluorouracil seemed even more effective.177

When a sponge soaked with 0.05% mitomycin C was placed on the trabeculectomy bed for 0.5 to 1 minute, the intraocular hypotensive effect at 30 to 36 months postoperative was similar to that achieved with a 3- to 5-minute application and was significantly better than placebo.178 A 2-minute application of 0.02% mitomycin C was as effective as a 5-minute exposure but the complication rates were the same.179 At 2 years, a 5-minute application of 0.05% mitomycin C was associated with a 78% reduction in intraocular pressure and with the need for fewer medications, but there was a 2.2% incidence of bacterial endophthalmitis and a 4.5% incidence of revision-requiring hypotony.180

Mitomycin 0.04%, held in the scleral bed for 5 minutes produced similar lens and corneal endothelial cell changes as injecting a total of 50 to 80 mg of fluorouracil subconjunctivally for a 3-week period: 27% in both groups had evidence of cataract progression and there was a 7% to 8% reduction in endothelial cells.181 Macular folds associated with hypotony occurred in 6.4% of patients in each treatment group using 0.02% mitomycin for 2 minutes, 0.02% mitomycin for 4 minutes, or 0.04% mitomycin for 2 minutes; the visual acuity recovered fully in one-third of these patients.182 In a study of 123 trabeculectomy eyes in which mitomycin C had been used 5 years previously, the mean preoperative intraocular pressure had been 25.8 mm Hg and at 5 years postoperative was 9.9 mm Hg.183 The incidence of hypotony maculopathy was 8.9%, of bleb leak was 14.6%, of bleb infection was 5.7%, and of endophthalmitis was 0.8%. Cataract surgery was performed in 55.3% of the eyes during the follow-up period. Repeat trabeculectomy for bleb failure was performed in 4.9% of eyes and trabeculectomy revision, primarily to increase filtration, was performed in 8.9% of eyes.

Using human donor eyes, it was shown that irrigation after applying mitomycin C reduced the superficial scleral concentration by approximately 50% but left the deep intrascleral concentration unchanged.184 The deeper sclera could act as a drug reservoir. This might contribute to both the efficacy and toxicity/side effects of the drug. To reduce the latter, mitomycin has been applied postoperatively to the filtering bleb only. Sponges with 0.005% mitomycin C were placed on the filter bleb for 5 minutes each on days 1, 2, and 3 postoperatively.185 The technique appeared equally effective to intraoperative application and the complication incidence was lower when evaluated at 1 year postoperatively.186

Intraoperative application of mitomycin C has been studied in several glaucoma subgroups:

  1. In trabeculectomy patients with simultaneous cataract phacoemulsification and pseudophakic implantation. Two prospective masked randomized studies found that use of mitomycin C improved glaucoma control.187,188 However, another prospective randomized study found mitomycin C of no additional benefit.189 There was weak evidence that mitomycin might reduce the incidence of subsequent posterior capsular opacification.190
  2. In pseudophakic patients subsequently undergoing trabeculectomy. Intraoperative mitomycin C and post-operative subconjunctival injections of 5-fluorouracil appeared equally effective in controlling glaucoma191 and had similar incidences of complications.
  3. In combined penetrating keratoplasty and trabeculectomy. In a retrospective analysis of 22 patients, use of intraoperative mitomycin C was associated with a 60% incidence of graft survival and a 50% incidence of glaucoma control at 2 years.192
  4. In normal tension glaucoma. A retrospective study found that, despite producing a greater hypotensive effect than 5-fluoroouracil, mitomycin C use during trabeculoplasty was associated with an increased risk of visual field loss.193
  5. In pediatric glaucoma. Trabeculectomy with mitomycin is usually effective in helping to lower the intraocular pressure, but there is a relatively high incidence of late bleb infections: 8% in one study and 17% in another.194,195
  6. In angle recession glaucoma. A retrospective analysis of 41 patients found a 66% cumulative probability of successful intraocular pressure control 3 years after intraoperative 0.02% mitomycin.196
  7. In iridocorneal endothelial syndrome. Seven of 10 eyes were well-controlled with a mean intraocular pressure of 12 mm Hg. An eighth patient had hypotony maculopathy and the two other patients required setons.197
  8. In seton implants. Conflicting results were reported in two retrospective studies. Mitomycin-C appeared of value when used as an adjuvant for a double-plate Molteno implant; the success rate at 1 year was 68%.198 However, in the other study in which a single-plate Molteno implant was used, the success rate at 1 year was lower than a historical control group.199

A different type of filtering procedure is the optic nerve sheath fenestration used for treating the elevated cerebral spinal fluid pressure causing pseudotumor cerebri. Scarring down of the incisional opening is a common cause of failure. Six patients had their optic nerve sheaths treated for 5 minutes with mitomycin C, 0.05%, before the incision was made through this dural tissue.200 In 4 patients the procedure was successful. The fifth patient required a neurosurgical shunt and the sixth required a repeat sheath fenestration. There were no toxicities or side effects that could be attributed to the use of mitomycin.



Cyclosporin A is a fungal metabolite with potent immunosuppressant activity and relatively little bone marrow toxicity. It has markedly improved the success of organ transplantation, especially renal transplantation. Cyclosporine is a cyclic polypeptide consisting of 11 amino acids.201 It has several unusual structural features, which include having a D-alanine, rather than the usual L-form, and having seven N-methylated amino acids. This latter may contribute to its resistance to gastrointestinal degradation, allowing the drug to be given orally. Cyclosporine has about 30% bioavailability, but there is marked interindividual variability. 202 Newer formulations of cyclosporine with better bioavailability have been developed, as have more potent and/or less toxic fungal metabolites, e.g., tacrolimus and cyclosporine G. 203–206

Cyclosporine specifically inhibits T-lymphocyte function with minimal activity against B cells. Maximum suppression of T-lymphocyte proliferation requires that the drug be present during the first 24 hours of antigenic exposure. It is much more effective in preventing the primary immune response than in preventing the secondary response by the sensitized cytotoxic lymphocytes. Cyclosporine interferes with the ability of helper T cells to induce a cellular immune response to an antigen. The drug inhibits interleukin II production, a factor necessary for the induction of cytotoxic T-lymphocyte proliferation.207–209 Other cyclosporine effects are the reduction in prostacyclin synthesis and the competition with prolactin for a common binding site on the surface of the T-lymphocytes.210,211

Cyclosporine is extensively metabolized by cytochrome P–450 liver microsomal enzymes. Most of the drug is excreted by the gastrointestinal tract even after intravenous administration. Oral doses of the drug for organ transplant patients usually range from 10 to 50 mg/kg per day. Monitoring the blood level of cyclosporine provides optimum management of dosage.

The most important toxicity produced by cyclosporin A is to the kidneys. Awareness of this problem has resulted in use of lower doses and more rapid tapering. In a retrospective analysis of 1663 renal transplant recipients with median follow-up of 3 years, there was little evidence of progressive toxic nephropathy from cyclosporine use.212 A potentially lethal form of lymphoma, associated with Epstein-Barr viral infection, is reversible if the drug is stopped.213Although immunosuppressive agents, in general, are associated with an increase incidence of lymphomas, there is no evidence that cyclosporine treatment poses a greater risk than the other drugs.214

Cyclosporin, 2% in olive oil, was given to one eye of 30 normal volunteers, two drops every 6 hours for 12 applications. Aqueous humor levels were assayed from different groups of five subjects over a 12-hour period after the last drop. The maximum aqueous humor level occurred at 4 hours with a mean ± standard deviation (SD) value of 24 ± 9 μg/ML.215 In seven patients reeiving oral cyclosporin A after keratoplasty, the blood levels of unmetabolized and metabolized drug were, respectively, 100 to 150 nanograms and 100 to 702 nanograms per ML blood. The corresponding aqueous humor levels ranged from 58 to 540 nanograms per ML. 216

A number of rabbit studies have shown that cyclosporin A, applied topically,217–221 injected retrobulbarly,222 or given systemically by intramuscular injection,223–225 prolonged the survival of corneal grafts and/or reduced the incidence of graft rejection. Topical cyclosporine has been used to treat 11 high-risk corneal transplant patients, i.e., those having previous graft failures, large areas of deep stromal vascularization, or previous severe alkali burns.226 Cyclosporin A, 2% in olive oil, was administered every 2 hours while awake beginning 1 to 2 days before surgery. After 4 days of treatment, cyclosporine drop frequency was reduced to four times per day for 3 months; topical corticosteroids were also given. Ten of the 11 patients had clear corneas during the follow-up periods that ranged from 6 to 24 months. Good results have been reported for treating corneal graft rejections refractory to corticosteroid therapy.227 Cyclosporine A 0.5% was instilled 4 to 6 times per day in 16 eyes. Nine eyes were cured within 11 weeks, and six other eyes were much improved and one eye failed to respond. Hill228 compared the results in high-risk corneal transplant patients treated with corticosteroids to those given corticosteroids plus systemic cyclosporine. The initial cyclosporine dose, 15 mg/kg per day, was given intravenously at surgery and the next day followed by 7.5 mg/kg per day for 2 days. The dose was then adjusted to maintain a level of 250 to 400 nanograms/ML whole blood; this usually required 4 to 4.5 mg/kg per day. Treatment was initially for a year, but the results appeared as good when maintained only 4 months. The use of systemic cyclosporine significantly improved the results of surgery. Of the 18 patients treated, one rejection occurred 13 months after transplantation (1 month after a complete course of treatment); one occurred 3 months after transplantation (2 months after discontinuing treatment because of an allergic reaction to cyclosporine); and three additional grafts had transient but successfully treated rejection episodes. Eighty-nine percent of the cyclosporine-plus-corticosteroid treated corneas were surviving at a mean length of 21.6 months (range 12 to 49 months) after surgery. The same author reported a subsequent series of high-risk keratoplasty patients who benefited from systemic cyclosporine. However, keratolimbal allografts had a poor 2-year survival rate despite use of topical and systemic cyclosporine.229 Others have failed to find sufficient benefit, compared to corticosteroid treatment230–232 alone to justify the potential toxicity and cost of cyclosporine treatment.

Oral cyclosporine has been used, with apparent efficacy, to treat corneal melting syndromes such as Mooren's ulcer, and those associated with rheumatoid arthritis and Wegener's granulomatosis.233–237 Cyclosporin A, e.g., 2.5 mg per kg per day, was used in conjunction with corticosteroids. Successful treatment using topical 2% cyclosporin A has been reported in rheumatoid corneal ulcerations.238

Conjunctiva from atopic eyes before and after 3 months of treatment with topical 2% cyclosporin A drops or placebo demonstrated significant drug effects: the total number of leukocytes, CD3+T cells, CD4+ cells, CD8+ cells, CD20+B cells, neutrophils, and macrophages were reduced.239 Topical cyclosporin A, 2% drops and 4% ointment, has been used with good results in ligneous conjunctivitis and vernal conjunctivitis.240,241 However, in vernal conjunctivitis, symptoms usually rapidly recurred when treatment was stopped.

Topical and systemic administration of cyclosporine improved the subjective symptoms of patients with dry eyes, but has not consistently improved their lacrimation as measured using the Schirmer's test.242,243 Treatment increased the number of goblet cells and reduced the conjunctival epithelium turnover rate.244 When lacrimal fluid production was measured in seven kidney transplant patients, it did increase during systemic cyclosporin A treatment.245 Before cyclosporine treatment, the mean ±standard error tear production was 19.4±1.5 mm of Schirmer strip wetting per 4 minutes. After 1 to 2 months of cyclosporine treatment, the tear production was 28.4±2.4 mm per 4 minutes (p<0.01) and after 9 to 18 months of treatment the tear production was 24.4±2.1 mm per 4 minutes (p<0.05). Cyclosporine 0.05% topically is of more limited value in increasing tear fluid production. Only 15% of approximately 1200 patients treated 6 months twice per day showed an increase in Schirmer wetting. No significant improvement was found in those patients simultaneously using topical antiinflammatory drugs or using punctal plugs, suggesting these other modalities were as effective. Using this twice per day eye drop regimen, blood levels of cyclosporin A were below the detection level of 0.1 ng/ML. There were no increased incidences of bacterial or yeast infections.246 Ocular burning occurred in 17% of patients. Conjunctival hyperemia, epiphora or foreign body sensation occurred in 1% to 5% of patients. Similar application of 0.1% cyclosporin A eye drops resulted in 5.5% (7 of 128) of patients having resultant blood levels of 0.1 ng/ML or higher; none of the blood levels exceeded 0.3 ng/ML.247

Cyclosporin A, administered systemically, has been effective in reducing the severity of uveitis in experimental animals.248–252 Aqueous humor and cerebrospinal fluid samples were obtained 6 and 24 hours, respectively, after the last ingestion of oral cyclosporin A in patients with mild uveitis. The frequencies and doses of the drug were not stated. The mean aqueous humor cyclosporine concentration, 44 ng/ML, was 40% ± 24% (mean ± SD) that of the plasma level.253 Cyclosporine was not detectable in the cerebrospinal fluid; the limit of sensitivity of the assay method was not stated.

Cyclosporine can be effective in patients with posterior uveitic diseases who are resistant to corticosteroid treatment. Behçet's disease, idiopathic uveitis, pars planitis, sarcoidosis, sympathetic ophthalmia, birdshot chorioretinopathy, and Vogt-Koyanaga-Harada syndrome have all been treated successfully.254–259 The initial dose was 10 mg/kg per day, which was then titrated according to clinical response or to a protocol. Some patients required a maintenance dose of 15 mg/kg per day,255 whereas others only needed 2 mg/kg per day.256 Patients were evaluated by visual acuity, fluorescein angiogram, and a subjective estimation of the severity of inflammation. In general, visual acuity improved within the first 2 weeks. Although the uveitis of Behçet's disease was better controlled by cyclosporine, systemic symptoms, such as skin lesions and arthritis, were not.257 Control of uveitis was maintained for prolonged periods (years). A small number of patients could eventually be weaned away from the drug without experiencing recurrences. BenEzra and co-workers258 reported that prolonged discontinuation of cyclosporine was possible in four of 24 patients. A patient with coexisting multiple sclerosis not only had her uveitis improve but also had her neurologic status improve, including P100 latency on visual evoked response testing; as multiple sclerosis, like uveitis, waxes and wanes spontaneously, the patient's neurologic improvement could not be attributed with certainty to cyclosporine.260

Optimum control of inflammation, while maintaining stable renal function, was achieved for a mean ±standard deviation of 16±10 months in a group of 8 patients with bilateral steroid-resistant azathioprine-resistant uveitis by adjusting the cyclosporine blood level 6 hours after the morning dose to 150 to 250 nanograms per ML. The mean dose was 3.9±1.4 mg/kg per day.261

Cyclosporin A has been reported to suppress idiopathic orbital inflammatory pseudotumor in a diabetic patient who could not tolerate corticosteroids.262 She was begun on 5 mg/kg per day and maintained for 10 months on 2 mg/kg per day. When the drug was discontinued her symptoms returned and she was treated with 2000 cGy. Proptosis in thyroid ophthalmopathy has also responded to cyclosporine, as well as extraocular muscle swelling and dysfunction.263–266 Initial doses of cyclosporine varied from 3 to 10 mg/kg per day. However, not all patients improved, which might have been the result of permanent fibrotic changes that occurred prior to initiating therapy.267–269

It was hoped that the toxicity of cyclosporine would be qualitatively different in patients not as ill and debilitated as those requiring major organ, e.g., kidney and liver, transplantation. Unfortunately, this does not seem to be the case. Renal toxicity remains a major problem with higher doses and prolonged usage.270 Palestine and co-workers271 reported nephrotoxicity in eight of 26 patients treated more than 1 month for uveitis. In these eight patients, the creatinines rose by more than 1.6 mg/dL in males and 1.3 mg/dL in females. Reduction in the dose of cyclosporine normalized the renal function in 3 to 4 weeks. However, Deray and co-workers272 reported only a partial return to normal values. Moreover, renal biopsy of patients receiving cyclosporine for an average of 2 years showed interstitial fibrosis and/ or tubular atrophy even in those with normal renal function.273 Other cyclosporine side effects have included hepatotoxicity, hypomagnesemia, hirsutism, gingivitis, and dysesthesias. Central nervous system symptoms and findings associated with cyclosporine have been visual hallucinations, transient cortical blindness, disc edema, and occipital lobe seizures.274–277 It may be that some of these effects were caused by graft-versus-host-disease after bone marrow transplantation when inadequate levels of cyclosporine were being used. The acute form of graft-versus-host-disease develops 3 to 4 weeks after bone marrow transplantation and in up to 80% of patients; it is characterized by hepatic dysfunction and skin and muscle changes. The chronic form, developing 3 to 6 months after bone marrow transplantation and in up to 50% of patients may, in addition, cause corneal epithelial defects, corneal melting, retinal cotton wool spots and hemorrhages, and optic disc edema.278,279

Tacrolimus, like cyclosporin, is a macrolide immunosuppressant produced by a fungus. It is much more potent and no more toxic than cyclosporine. The drug has at least two actions. It inhibits T-lymphocyte activation possibly by limiting interleukin-2 gene expression in T-helper lymphocytes. In addition, tacrolimus binds to the steroid receptor-associated heat-shock protein 56, which results in transcription inhibition of proinflammatory cytokine formation including granulocyte-macrophage colony-stimulating factor, interleukins-1, 3, 4, 5, 6, and 8, and tumor necrosis factor alpha. Bioavailability after oral administration is variable, between 5% and 65%, and can be reduced depending on the type of food ingested. Approximately 99% of the absorbed drug is metabolized by the liver. Systemic administration is associated with increased incidences of nephrotoxicity, neurotoxicity (hallucinations, tremors, confusion, and seizures) and new-onset diabetes. Tacrolimus is available in oral, injectable, and topical preparations. Oral capsules contain 1 mg or 5 mg tacrolimus. The injectable form contains 5 mg per ML. For adults, 0.03% and 0.1% ointments are available, and for children a 0.03% ointment is available.

Topical tacrolimus 0.03%, twice per day to each eye lid, has been used successfully in a small number of adult subjects, ages 44 to 62 years, with atopic blepharitis refractory to topical corticosteroid treatment.280 Eyelid erythema and eczema were substantially reduced in 1 to 3 weeks. Patients were able to discontinue topical corticosteroid use. No adverse effects were noticed after continuous treatment for 5 to 14 months.

Systemic tacrolimus, 2 to 12 milligrams per day, has been successfully used for periods of 12 to 46 months to prevent corneal and limbal epithelial allograft rejections.281 Trough levels of 10 to 20 nanograms tacrolimus per ML of blood have been sufficient to control ocular surface breakdown in graft-versus-host disease282 resistant to cyclosporine treatment. Six patients with posterior ocular inflammatory disease were treated by using trough levels of 1 to 15 nanograms tacrolimus per ML blood.283 Three patients had Behcet's uveitis, one had pars planitis, and two had retinal vasculitis. Four of the patients had not responded adequately to cyclosporine and prednisolone therapies and two of the patients had demonstrated cyslosporine toxicity. The ocular uveitis and vasculitis were adequately controlled while on tacrolimus. Duration of treatment was from 4 to 23 months.


Etoposide is derived from podophyllotoxin. Its mechanism of action is unknown. It is a topoisomerase II inhibitor that inhibits DNA synthesis premitosis, with maximum effects during the S and G2 phases of cell division. It can be administered orally or parenterally. More of the drug is renal excreted than is gastrointestinal excreted. Etoposide produces anemia, leukopenia, and thrombocytopenia.

Etoposide has been used with irradiation and in combination with vincristine and ifosfamide to treat rhabdomyosarcoma of the orbit. It has been in combination with vincristine and carboplatin in the treatment of retinoblastoma.284



Dapsone, a sulfone, is effective in suppressing mucocutaneous bullous eruptions. Its mechanism of action is unknown. IgA levels and complement deposition are not affected. The drug has been successfully used in mild to moderate ocular cicatricial pemphigoid.285 Its chief unwanted side effect is hemolytic anemia. Azulfidine, a precursor of sulfapyridine, and sulfapyridine have also been shown to be similarly effective.286,287 Azulfidine use was associated with hemolytic anemia in two of nine patients; this problem did not occur in any of the 20 patients taking sulfapyridine.


The naturally occurring interferons are cytokines with immunoregulatory, antiviral, antitumor and cell growth regulatory functions. There are three subtypes: alpha, beta, and gamma interferons. Two beta recombinant products that are available are interferon beta-1a and interferon beta-1b. Their 161 amino acid structures differ in only two ways: interferon beta-1a is glycosylated at amino acid 80 and they have one different amino acid. Both have little tendency to stimulate antibody production against them because they are so similar to the natural occurring beta interferon. However, large doses and frequent use can cause an immune response.

These beta interferons are available for the treatment of multiple sclerosis. The published studies defining their value do not separate out their effectiveness in preventing recurrent optic neuritis. However, in one major study, 50% of the subjects presented with optic neuritis and two or more “clinically silent” brain MRI lesions.288,289 Interferon beta-1a was begun after initial treatment with intravenous methylprednisolone (1 gram per day for 3 days) followed by oral prednisone (1 mg per kg for 11 days and then tapering doses on days 12 to 14). After the intravenous methylprednisolone, weekly intramuscular injections of interferon beta-1a were begun, using 30 micrograms or placebo. During the 3-year follow-up, the group treated with interferon beta-1a had a significantly lower probability of developing clinically definite multiple sclerosis and a higher probability of reductions in the volume of MRI identified brain lesions and the number of new and enlarging lesions. However, the majority of patients treated with interferon beta-1a developed evidence of progressive disease within 3 years. The evidence of clinically definite multiple sclerosis was 28% in interferon-treated patients and 37% in placebo-treated patients; an additional 33% and 38% of treated and placebo patients, respectively, had MRI evidence of progression.

The progressive course of multiple sclerosis has generally been divided into five types: relapsing-remitting, primary progressive, secondary progressive, progressive-relapsing, and acute rapidly progressive.290 Treatment for 4 years of relapsing-remitting multiple sclerosis, defined as existing in patients demonstrating at least two relapses in the previous 2 years, demonstrated that interferon beta-1a therapy was associated with a reduction in new relapses and MRI lesions.291 However, in a 3-year study of secondary progressive multiple sclerosis, interferon beta-1a did not significantly alter disability progression.292 In patients receiving three times per week doses of interferon beta-1a of 22 micrograms and 44 micrograms, the incidences of neutralizing antibodies over a 4-year period were, respectively, 23.7% and 14.3%; presence of neutralizing antibodies was associated with a reduced therapeutic response.

Interferon alphas are available in two forms, 2a and 2b. Topical alpha interferon was of no value in reducing viral shedding or the clinical duration of adenovirus conjunctivitis.293 Subconjunctival injections of interferon alpha in four of five patients with conjunctival lymphomas provided complete resolution for the 12- to 36-month follow-up periods.294 Subconjunctival and perilesional injections of interferon alpha-2b produced complete clinical resolution of intraepithelial neoplasia in five patients with this sqamous cell carcinoma-precursor condition. However, the follow-up range was only 2 to 11 months.295 Case reports of only one or two patients have indicated success in treating conjunctival papillomata (topical treatment), Mooren's ulcer associated with hepatitis-C (systemic treatment) renal cell carcinoma metastatic to the iris (systemic treatment) and orbital hemangioma (systemic treatment).296–299 The majority of patients weith choroidal neovascular membranes causing macular degeneration failed to show any antiangiogenic benefit from systemic administration of interferon alpha-2A.300–303 However, antibodies to interferon alpha-2A have been detected in 24 of 34 (71%) of patients receiving the drug, which may explain the poor results.304

The primary adverse side effect with interferon treatment has been a flu-like syndrome, but leukopenia, fever, and nausea also can develop.

Mycophenolate Mofetil

Mycophenolate mofetil is an orally administered drug which is de-esterified to its active metabiolite, mycophenolic acid, a noncompetitive reversible inhibitor of inosine monophosphate dehydrogenase. This inhibits synthesis of purine nucleotides and DNA resulting in reduced T and B cell proliferation. The drug also inhibits B lymphocyte formation of antibody. Mycophenolate mofetil, in doses of 2 grams per day, was effective in controlling refractory uveitis in 18 of 20 patients encompassing two studies. The doses of corticosteroids and cyclosporine could frequently be reduced.305,306 Side effects were generally mild.

In a prospective randomized trial of keratoplasty patients considered at high risk for failing, 21 patients received mycophenolate mofetil, 2 grams per day, and corticosteroids. Another 20 patients received cyclosporin A, in doses achieving whole blood trough levels of 120 to 150 nanograms per ML, and corticosteroids. Mycophenolate mofetil and cyclosporin A were equally effective; two patients in each subgroup showed signs of graft rejection within the first 6 postoperative months.307


Antitumor Necrosis Factor Antibodies

Tumor necrosis factors alpha and beta (the latter also, confusingly, referred to as lymphotoxin alpha) are cytokines produced by macrophages and T-cell lymphocytes. Both of these tumor necrosis factors react with two different receptors on cell surfaces. Etanercept is a soluble form of one of the receptors. It binds to both types of tumor necrosis factors, rendering them inactive. Etanercept is of proven value in treating active rheumatoid arthritis. A side effect is an increased incidence of infections and its use should be discontinued if one develops or if there is an exposure to Herpes zoster. Infliximab is a monoclonal antibody that binds specifically to tumor necrosis factor alpha but not to tumor necrosis factor beta. Infliximab is of proven efficacy in treating active rheumatoid arthritis and active Crohn's disease. Use of the antitumor necrosis factor therapies may result in antibody formation. Rarely does this antibody cause a lupus-like autoimmune syndrome.

In a masked randomized prospective study of 20 uveitis patients controlled with methrotrexate, half were treated with etanercept, 25 mg subcutaneously twice weekly and half placebo.308 Methrotrexate taper was begun 2 weeks after the first injection. Two patients prematurely left the etanercept group for reasons unrelated to the drug's effects. Three of eight patients in the entanercept group and five of 10 patients in the placebo group had relapses of their uveitis. There was no significant benefit to using etanercept.

In a prospective but uncontrolled study of seven patients with acute onset HLA—B27-associated anterior uveitis, a single dose of infliximab seemed of value in controlling the inflammation.309 A single case report of an 18 year old with Behcet's disease uveitis uncontrolled with systemic corticosteroids stated that infliximab 5 mg/kg intravenously at weeks 0, 2, 4, and 8 was associated with a complete remission not only of the uveitis but also of all systemic findings by the time of the second injection.310 The remission was maintained for up to 8 weeks after the last injection.

Back to Top

1. Wilson MW, Rodriquez-Galindo C, Haik BG: Multiagent chemotherapy as neoadjuvant treatment for multifocal intraocular retinoblastoma. Ophthalmology 108:2106, 2001

2. Shields CL, Honavar SG, Shields JA, et al: Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 120:460, 2002

3. Lumbroso L, Doz F, Urbieta M: Chemothermotherapy in the management of retinoblastoma. Ophthalmology 109:1130, 2002

4. Honavar SG, Singh AD, Shields CL, et al: Postenucleation adjuvant therapy in high-risk retinoblastoma. Arch Ophthalmol 120:923, 2002

5. Dunkel IJ, Aledo A, Kernan NA: Successful treatment of metastatic retinoblastoma. Cancer 89:2117, 2000

6. Harris CC: The carcinogenicity of anticancer drugs: A hazard in man. Cancer 37:1014, 1976

7. Penn I: Second malignant neoplasms associated with immunosuppressive medications. Cancer 37:1024, 1976

8. Klingele TG, Hogan MJ: Ocular reticulum cell sarcoma. Am J Ophthalmol 79:39, 1975

9. Andrasch RH, Pirofsky B, Burns RP: Immunosuppressive therapy for severe chronic uveitis. Arch Ophthalmol 96:247, 1978

10. Wolff JA, Pratt CB, Sitarz AL: Chemotherapy of metastatic retinoblastoma. Cancer Chemother Rep 16:435, 1962

11. Abramson DH, Ellsworth RM, Tretter P, et al: The treatment of orbital rhabdomyosarcoma with irradiation and chemotherapy. Ophthalmology 86:1330, 1979

12. de Smet MD, Stark-Vancs V, Kohler DR, et al: Intraocular levels of methrotrexate after intravenous administration. Am J Ophthalmol 121:442, 1996

13. Fishburne BC, Wilson DJ, Rosenbaum JT, et al: Intravitreal methrotrexate as an adjunctive treatment of intraocular lymphoma. Arch Ophthalmol 115:1152, 1997

14. Smith JR, Rosenbaum JT, Wilson DJ, et al: Role of intravitreal methrotrexate in the management of primary central nervous system lymphoma with ocular involvement. Ophthalmoology 109:1709, 2002

15. Wong VG, Hersh EM: Methotrexate in the therapy of cyclitis. Trans Am Acad Ophthalmol Otolaryngol 69:279, 1965

16. Wong VG: Immunosuppressive therapy of ocular inflammatory diseases. Arch Ophthalmol 81:628, 1969

17. Wong VG, Hersh EM, McMaster PRB: Treatment of a presumed case of sympathetic ophthalmia with metho-trexate. Arch Ophthalmol 76:66, 1966

18. Lazar M, Weiner MJ, Leopold IH: Treatment of uveitis with methotrexate. Am J Ophthalmol 67:383, 1969

19. Owen ET, Cohen ML: Methotrexate in Reiter's disease. Ann Rheum Dis 38:48, 1979

20. Foster CS, Kenyon KR, Greiner J, et al: The immunopathology of Mooren's ulcer. Am J Ophthalmol 88:149, 1979

21. Foster CS: Immunosuppressive therapy for external ocular inflammatory disease. Ophthalmology 87:140, 1980

22. Maust HA, Foroozan R, Sergott RC, et al: Use of methrotrexate in sarcoid-associated optic neuropathy. Ophthalmology 110:559, 2003

23. Mazzantini M, Munno O: Methrotrexate and bone mass. Experimental Rheumatol 18(suppl 21):587, 2000

24. Cranney AB, McKendry RJ, Wells GA, et al: The effect of low dose methrotrexate on bone density. J Rheumatol 28:2395, 2001

25. Hernandez-Garcia C, Soriano C, Morado C, et al: Methrotrexate treatment in the management of giant cell arteritis. Scand J Rheumolol 23:295, 1994

26. Jover JA, Hernandez-Garcia C, Morado IC, et al: Combined treatment of giant-cell arteritis with methrotrexate and prednisone. Ann Intern Med 134:106, 2001

27. Spiera RF, Mitnick HJ, Kupersmith M: A prospective, double-blind randomized, placebo controlled trial of methrotrexate in the treatment of giant cell arteritis. Clionic Exper Rheumatol 19:495, 2001

28. Hoffman GS, Cid CC, Hellmann DB: A multicenter, randomized, double-blind placebo-controlled trial of adjuvant methrotrexate treatment for giant cell arteritis. Arthritis and Rheumatism 46:1309, 2002

29. Midena E, Angeli CD, Valenti M, et al: Treatment of conjunctival squamous cell carcinoma with topical 5-fluorouracil. Br J Ophthalmol 84:268, 2000

30. Yamamoto N, Ohmura T, Suzuki H, et al: Successful treatment with 5- fluorouracil of conjunctival intraepithelial neoplasia refractive to mitomycin-C. Ophthalmology 109:249, 2002

31. Yeatts RP, Engelbrecht NE, Curry CD, et al: 5-Fluorouracil for the treatment of intraepithelial neoplasia of the conjunctiva and cornea. Ophthalmology 107:2190, 2000

32. Maldonado MJ, Cano-Parra J, Navea-Tejerina A, et al: Inefficacy of low-dose intraoperative fluorouracil in the treatment of primary pterygium. Arch Ophthalmol 113:1356, 1995

33. Hajek AS, Parrish RK II , Mallick KS, Gressel M: In vitro inhibition of ocular cell proliferation with Ara-C: Blockage of the antiproliferative effect with 2'-deoxycytidine. Invest Ophthalmol Vis Sci 27:1010, 1986

34. Shaikh AA, Damji KE, Mintsioulis G, et al: Bilateral epithelial downgrowth managed in one eye with intraocular 5-fluorouracil. Arch Ophthalmol 12:1396, 2002

35. Libre PE: Transient, profound cataract associated with intracaperal 5- luorouracil. Am J Ophthalmol 135:101, 2003

36. Lai MM, Haller JA: Resolution of epithelial ingrowth in a patient treated with 5-fluorouracil. Am J Ophthalmol 133:562, 2002

37. Heath TD, Lopez NG, Lewis GP, Stern WH: Fluoropyrimidine treatment of ocular cicatricial disease. Invest Ophthalmol Vis Sci 27:940, 1986

38. Stern WA, Lewis GP, Erickson PA, et al: Fluorouracil therapy for proliferative vitreoretinopathy after vitrec-tomy. Am J Ophthalmol 96:33, 1983

39. Blumenkranz MS, Hartzer MK, Hajek AS: Selection of therapeutic agents for intraocular proliferative disease. Arch Ophthalmol 105:396, 1987

40. Blankenship GW: Evaluation of a single intravitreal injection of 5-fluorouracil in vitrectomy cases. Graefes Arch Clin Exp Ophthalmol 229:565, 1989

41. Blumenkranz M, Hernandez E, Ophir A, Norton EWD: 5-Fluorouracil: New applications in complicated retinal detachment for an established antimetabolite. Ophthalmology 91:122, 1984

42. Asaria RHY, Kon CH, Bruce C, et al: Adjuvant 5-fluorouracil and heparin prevents proliferative vitreoretinopathy. Ophthalmology 108:1179, 2001

43. Nobuhisa NI, Honda Y: Toxic effect of fluorouracil on the rabbit retina. Am J Ophthalmol 96:641, 1983

44. Stern WH, Guerin CJ, Erickson PA, et al: Ocular toxicity of fluorouracil after vitrectomy. Am J Ophthalmol 96:43, 1983

45. Orr G, Tervaert DC, Lean JS: Aqueous concentrations of fluorouracil after intravitreal injection. Arch Ophthalmol 104:431, 1986

46. Blumenkranz MS, Claflin A, Hajek AS: Selection of therapeutic agents for intraocular proliferative disease: Cell culture evaluation. Arch Ophthalmol 102:598, 1984

47. Kondo M, Araie M: Concentration change of fluorouracil in the external segment of the eye after subconjunctival injection. Arch Ophthalmol 106:1718, 1988

48. Shapiro MS, Thoft RA, Friend J, et al: 5-Fluorouracil toxicity to the ocular surface epithelium. Invest Ophthalmol Vis Sci 26:580, 1985

49. Heuer DK, Gressel MG, Parrish RK II , et al: Topical fluorouracil post-operative administration in an animal model of glaucoma filtering surgery. Arch Ophthalmol 104:132, 1986

50. Weinreb RN: Adjusting the dose of 5-fluorouracil after filtration surgery to minimize side effects. Ophthalmology 94:564, 1987

51. Rockwood EJ, Parrish RK II , Heuer DK, et al: Glaucoma filtering surgery with 5-fluorouracil. Ophthalmology 94:1071, 1987

52. Ruderman JM, Welch DB, Smith MF, Shoch DE: A randomized study of 5-fluorouracil and filtration surgery. Am J Ophthalmol 104:218, 1987

53. Tsai JC, Feuer WJ, Parrish II RK, et al: 5-Fluorouracil filtering surgery and neovascular glaucoma. Ophthalmology. 102:887, 1995

54. Knapp A, Heuer DK, Stern GA, Driebe WT: Serious corneal complications of glaucoma filtering surgery with post-operative 5-fluorouracil. Am J Ophthalmol 103:183, 1987

55. Fluorouracil Filtering Surgery Study Group: Fluorouracil filtering surgery study one-year follow-up. Am J Ophthalmol 108:625, 1989

56. Krug JH, Melamed S: Adjunctive use of delayed and adjustable low-dose 5-fluorouracil in refractory glaucoma. Am J Ophthalmol 109:412, 1990

57. Fluorouracil Filltering Surgery Study Group: Five-year follow-up of the fluorouracil filtering surgery study. Am J Ophthalmol 121:349, 1996

58. Suzuki R, Dickens CJ, Iwach AG, et al: Long-term follow-up of initially successful trabeculectomy with 5-fluorouracil injections. Ophthalmology 109:1921, 2002

59. Chaudhry IA, Pasha MA, O'Connor DJ, et al: Randomized, controlled study of low-dose 5-fluorouracil in primary trabeculectomy. Am J Ophthalmol 130:700, 2000

60. Lanigan L, Sturmer J, Baez KA, et al: Single intraoperative applications of 5- fluorouracil during filtration surgery: early results. Br J Ophthalmol 78:33, 1994

61. Mora JS, Nguyen N, Iwach AG, et al: Trabeculectomy with intraoperative sponge 5- fluorouracil. Ophthalmology 103:963, 1996

62. Towler HMA, McCluskey P, Shaer B, et al: Long-term follow-up of trabeculectomy with intraoperative 5-fluorouracil for uveitis-related glaucoma. Ophthalmology 107:1822, 2000

63. Wudunn D, Cantor LB, Palanca-Capistrano AM, et al: A prospective randomized trial comparing intra-operative 5- fluorouracil vs mitomycin C in primary trabeculectomy. Am J Ophthal 134:521, 2002

64. Wirotsko E, Halbert SP: Suppression of allergic uveitis by 6-mercaptopurine. J Exp Med 116:653, 1962

65. Newell FW, Krill AE, Thomson A: The treatment of uveitis with six-mercaptopurine. Am J Ophthalmol 61:1250, 1966

66. Elliott JH, Leibowitz HM: The influence of immunosuppressive agents upon corneal wound healing. Arch Ophthalmol 76:334, 1966

67. Elliott JH, Leibowitz HM: Chemotherapeutic immunosuppression of the corneal graft reaction. Arch Ophthalmol 76:709, 1966

68. Leibowitz HM, Elliott JH: Chemotherapeutic immunosuppression of the corneal graft reaction. II. Arch Ophthalmol 76:338, 1966

69. Cleasby GW, Webster RG, Vincent NJ: Modification of the homograft reaction in corneal transplantation. Arch Ophthalmol 76:282, 1966

70. Burrow GN, Mitchell MS, Howard RO, Morrow LB: Immunosuppressive therapy for the eye changes of Graves' disease. J Clin Endocrinol Metab 31:307, 1970

71. Perros P, Weightman DR, Crombe AL, Kendall-Taylor P: Azathioprine in the treatment of thyroid-associated ophthalmopathy. Acta Endocrinol (Copenh) 122:8, 1990

72. Yazici H, Pazarli H, Barnes CG, et al: A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 322:281, 1990

73. Newell FW, Krill AE: Treatment of uveitis with azathioprine (Imuran). Trans Ophthalmol Soc UK 87:499, 196774

74. Moore CE: Sympathetic ophthalmitis treated with azathioprine. Br J Ophthalmol 52:688, 1968

75. Mathews JD, Crawford BA, Bignell JL, Mackay IR: Azathioprine in active chronic iridocyclitis. Br J Ophthalmol 53:327, 1969

76. Jayson MN, Jones DEP: Scleritis and rheumatoid arthritis. Ann Rheum Dis 30:343, 1971

77. Haynes BF, Fishman ML, Fauci AS, Wolff SM: The ocular manifestations of Wegener's granulomatosis. Am J Med 63:131, 1977

78. Foster CS, Wilson LA, Ekins MB: Immunosuppressive therapy for progressive ocular cicatricial pemphigoid. Ophthalmology 89:340, 1982

79. Hahnenberger RW: Influence of intraocular colchicine and vinblastine on the cat iris. Acta Physiol Scand 98:425, 1976

80. Bhattacherjee P, Eakins KE: The intraocular pressure lowering effect of colchicine. Exp Eye Res 27:649, 1978

81. Sellami M, Weil M, Dhermy P, et al: Adjuvant chemotherapy in ocular malignant melanoma. Oncology 43:221, 1986

82. Yunis JJ, Ramsay N: Retinoblastoma and subband deletion of chromosome 13. Am J Dis Child 132:161, 1978

83. Gipson IK, Westcott MJ, Brooksby NG: Effects of cytochalasins B and D and colchicine on migration of the corneal epithelium. Invest Ophthalmol Vis Sci 22:633, 1982

84. Gipson IK, Keezer L: Effects of cytochalasins and colchicine on the ultrastructure of migrating corneal epithelium. Invest Ophthalmol Vis Sci 22:643, 1982

85. Alster Y, Varssano D, Lowenstein A, et al: Delay of wound healing in patients treated with colchicine. Ophthalmology 104:118, 1997

86. Perisic M, Cuenod M: Synaptic transmission depressed by colchicine blockade of axoplasmic flow. Science 175:1140, 1972

87. Beebe DC, Feagans DE, Blanchette-Mackie EJ, Nau ME: Lens epithelial cell elongation in the absence of mi-crotubules: Evidence for a new effect of colchicine. Science 206:836, 1979

88. Mizushima Y, Matsumura N, Mori M, et al: Colchicine in Behçet's disease. Lancet 2:1037, 1977

89. Hijikata K, Masuda K: Visual prognosis in Behçet's disease: Effects of cyclophosphamide and colchicine. Jpn J Ophthalmol 22:506, 1976

90. Domeyer BE, Sladek NE: Kinetic of cyclophosphamide biotransformation in vivo. Cancer Res 40:174, 1980

91. McCarthy JC: Mechlorethamine hydrochloride treatment of experimental tuberculous uveitis. Arch Ophthalmol 66:95, 1961

92. Jampol LM, West C, Goldberg MF: Therapy of scleritis with cytotoxic agents. Am J Ophthalmol 86:266, 1978

93. Mamo JG, Azzam SA: Treatment of Behçet's disease with chlorambucil. Arch Ophthalmol 84:466, 1970

94. Abdalla MI, Bahgat NE: Long-lasting remission of Behçet's disease after chlorambucil therapy. Br J Ophthalmol 57:706, 1973

95. Godfrey WA, Epstein WV, O'Connor GR, et al: The use of chlorambucil in intractable idiopathic uveitis. Am J Ophthalmol 78:415, 1974

96. Dinning WJ, Perkins ES: Immunosuppressive in uveitis. Br J Ophthalmol 59:397, 1975

97. Mamo JG: Treatment of Behçet's disease with chlorambucil. Arch Ophthalmol 94:580, 1976

98. Tricoulis D: Treatment of Behçet's disease with chlorambucil. Br J Ophthalmol 60:55, 1976

99. Ohno S, Char DH, Kimura SJ, O'Connor GR: Vogt-Koyanagi-Harada syndrome. Am J Ophthalmol 83:735, 1977

100. Clay C, Bilaniuk LT, Vignaud J: Orbital pseudotumors: Preliminary report on a new type of therapy. Neuro-Ophthalmology 1:101, 1980

101. Jennings T, Tessler HH: Twenty cases of sympathetic ophthalmia. Br J Ophthalmol 73:140, 1989

102. Tabbara KF: Chlorambucil in Behçet's disease. Ophthalmology 90:906, 1983

103. Berk PD, Goldberg JD, Silverstein MN, et al: Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 304:441, 1981

104. Miller D: Alkylating agents and human spermatogenesis. JAMA 90:906, 1983

105. Kahn MF, Arlet J, Bloch-Michel H, et al: Leucemies aigues apres traitement par agents cytotoxiques en rhu-matologie 19: Observations chez 2006 patients. Nouv Presse Med 8:1393, 1979

106. Bedford MA, Bedotto C, Macfaul PA: Retinoblastoma: A study of 139 cases. Br J Ophthalmol 55:19, 1971

107. Malik RK, Friedman HS, Djang WT, et al: Treatment of bilateral retinoblastoma with vincristine and cyclophosphamide. Am J Ophthalmol 102:650, 1986

108. Bigos ST, Nisula BC, Daniels GH, et al: Cyclophosphamide in the management of advanced Graves' oph-thalmopathy. Ann Intern Med 90:921, 1979

109. Modabber F, Bear SE, Cerny J: The effect of cyclophosphamide on the recovery from a local chlamydial infection. Immunology 30:929, 1976

110. Oh JO: Effect of cyclophosphamide on primary herpes simplex uveitis in rabbits. Invest Ophthalmol Vis Sci 17:769, 1978

111. Dennis RF, Oh JO: Aspirin, cyclophosphamide, and dexamethasone effects on experimental secondary herpes simplex uveitis. Arch Ophthalmol 97:2170, 1979

112. Buckley CE, Gills JP Jr : Cyclophosphamide therapy of peripheral uveitis. Arch Intern Med 124:29, 1969

113. Brubaker R, Font RL, Shepherd EM: Granulomatous sclerouveitis. Arch Ophthalmol 86:517, 1971

114. Buckley CE, Gills JP Jr : Cyclophosphamide therapy of Behçet's disease. J Allergy 43:273, 1969

115. Hurd ER, Snyder WB, Ziff M: Choroidal nodules and retinal detachments in rheumatoid arthritis. Am J Med 48:273, 1970

116. Kende G, Sirkin SR, Thomas PRM, Freeman AL: Blurring of vision: A previously undescribed complication of cyclophosphamide therapy. Cancer 44:69, 1979

117. Garrity JA, Kennerdell JS, Johnson BL, Ellis LD: Cyclophosphamide in the treatment of orbital vasculitis. Am J Ophthalmol 102:97, 1986

118. Mondino BJ, Brown SL: Immunosuppressive therapy in ocular cicatricial pemphigoid. Am J Ophthalmol 96:453, 1983

119. Palmer RG, Dore CJ, Denman AM: Cyclophosphamide induces more chromosome damage than chlorambucil in patients with connective tissue disease. Q J Med 59:395, 1986

120. Pedersen-Bjergaard J, Ersboll J, Hansen VL, et al: Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 318:1028, 1988

121. Wheeler GE: Cyclophosphamide-associated leukemia in Wegener's granulomatosis. Ann Intern Med 94:361, 1981

122. Foster CS, Forstot SL, Wilson LA: Mortality rate in rheumatoid arthritis patients developing necrotizing scleritis or peripheral ulcerative keratitis. Ophthalmology 91:1253, 1984

123. Krementz ET, Schlosser JV, Rumage JP, Herring L: Retinoblastoma: Behavior and treatment with fractional radiation and intra-arterial triethylenemelamine. Ann NY Acad Med 114:963, 1964

124. Ellsworth RM: Treatment of retinoblastoma. Am J Ophthalmol 66:49, 1968

125. Bishop JO, Madson EC: Retinoblastoma: Review of the current status. Surv Ophthalmol 19:342, 1975

126. Reese AB, Ellsworth RM: The evaluation and current concept of retinoblastoma therapy. Trans Am Acad Ophthalmol Otolaryngol 67:164, 1963

127. Reese AB, Ellsworth RM: Management of retinoblastoma. Ann NY Acad Sci 114:958, 1964

128. Rock RL: Inhibition of corneal vascularization by triethylene thiophosphoramide (Thio-TEPA). Arch Ophthalmol 69:330, 1963

129. Ey RC, Hughes WF, Bloome MA, Tallman CB: Prevention of corneal vascularization. Am J Ophthalmol 66:1118, 1968

130. Liddy B, Morgan JF: Triethylene thiophosphoramide (Thio-tepa) and pterygium. Am J Ophthalmol 61:888, 1966

131. Olander K, Haik KG, Haik GM: Management of pterygia: Should Thio-tepa be used? Ann Ophthalmol 10:853, 1978

132. Cassady JR: The inhibition of pterygium recurrence by Thio-tepa. Am J Ophthalmol 61:886, 1966

133. Kleis W, Guillermo P: Thio-tepa therapy to prevent postoperative pterygium occurrence and neovascularization. Am J Ophthalmol 76:371, 1973

134. Meacham CT: Triethylene thiophosphoramide in the prevention of pterygium recurrence. Am J Ophthalmol 54:751, 1962

135. Asregadoo ER: Surgery, Thio-tepa, and corticosteroid in the treatment of pterygium. Am J Ophthalmol 74:960, 1972

136. Howitt D, Karp EJ: Side-effect of topical Thio-TEPA. Am J Ophthalmol 68:473, 1969

137. Joselson GA, Muller P: Incidence of pterygium recurrence. Am J Ophthalmol 61:891, 1966

138. Burns RP, Beighle R: Effects of triethylenethiophosphoramide on the carrageenin granuloma of the guinea pig cornea. Ophthalmol 1:666, 1962

139. Robertson DM, Creasman JP: Effects of topical Thio-tepa on rat eyes. Am J Ophthalmol 73:73, 1972

140. Berkow JW, Gills JP Jr , Wise JB: Depigmentation of eyelids after topically administered Thiotepa. Arch Ophthalmol 82:415, 1969

141. Liu HS, Perry HD, Refojo ME, Mukai N: Tolerance of DTIC in normal rabbit eyes. Metab Ophthalmol 2:33, 1978

142. Grimson BS, Mahaley MS Jr , Dubey HD, Dudka L: Ophthalmic and central nervous system complications following intracarotid BCNU (carmustine). J Clin Neuro-Ophthalmol 1:261, 1981

143. Miller DF, Bay JW, Lederman RJ, et al: Ocular and orbital toxicity following intracarotid injection of BCNU (Carmustine) and cisplatinum for malignant gliomas. Ophthalmology 92:402, 1985

144. Chrousos GA, Oldfield EH, Doppman JL, Cogan DG: Prevention of ocular toxicity of carmustine (BUNU) with supraophthalmic intracarotid infusion. Ophthalmology 93:1471, 1986

145. Liu HS, Refojo MF, Perry HD, Albert DM: Direct delivery of anticancer agents: Experimental treatment of intraocular malignancy. Invest Ophthalmol Vis Sci 17:993, 1978

146. Wilczek ZM: Experimental intraocular penetration of dacarbazine. Am J Ophthalmol 84:299, 1977

147. Tan C, Etcubanas E, Wollner N, et al: Adriamycin: An antitumor antibiotic in the treatment of neoplastic disease. Cancer 32:9, 1973

148. Luxenberg MN, Guthrie TH Jr : Chemotherapy of basal cell and squamous cell carcinoma of the eyelids and periorbital tissues. Ophthalmology 93:504, 1986

149. Meldrum ML, Tse DT, Benedetto P: Neoadjuvant intracarotid chemotherapy for treatment of advanced adenocystic carcinoma of the lacrimal gland. Arch Ophthalmol 116:315, 1998

150. Wirtschafter JD, McLoon LK: Long-term efficacy of local doxirubicin chemomyectomy in patients with blepharospasm and hemifacial spasm. Ophthalmology 105:342, 1998

151. Cummings J, Spanswick VJ, Tomasz M, et al: Enzymology of mitomycin C metabolic activation in tumorous tissue. Biochem Pharmacol 56:405, 1998

152. Shelonka LP, Siegel D, Wilson MW, et al: Immunohistochemical localization of NQO1 in epithelial dysplasia and neoplasia and in donor eyes. Invest Ophthalmol Vis Sci 41:1617, 2000

153. Hayasaka S, Noda S, Yamamoto Y, Setogawa T: Postoperative instillation of low-dose mitomycin C in the treatment of primary pterygium. Am J Ophthalmol 106:715, 1988

154. Amano S, Motoyama Y, Oshika T, et al: Comaprative study of intraoperative mitomycin C and? irradiation in pterygium surgery. Br J Ophthalmol 84:618, 2000

155. Singh G, Wilson MR, Foster CS: Mitomycin eye drops as treatment for pterygium. Ophthalmology 95:813, 1988

156. Frucht-Pery J, Siganos CS, Ilsar M: Intra-operative application of topical mitomycin C for pterygium surgery. Ophthalmology 103:674, 1996

157. Chen PP, Ariyasu, RG, Kaza V, et al: A randomized trial comparing mitomycin C and conjunctival autograft after excision of primary pterygium. Am J Ophthalmol 120:151, 1995

158. Cardillo JA, Alves MR, Ambrosio LE, et al: Single intra-operative application versus postoperative mitomycin C eye drops in pterygium surgery. Ophthalmology 102:1949, 1995

159. Manning CA, Kloess, PM, Diaz MD, et al: Intraoperative mitomycin in primary pterygium excision. Ophthalmology 104:844, 1997

160. Mutlu FM, Sobaci G, Tatar T, et al: A comparative study of recurrent pterygium surgery. Ophthalmology 106:817, 1999

161. Lam DSC, Wonk AKK, Fan DSP, et al: Intraoperative mitomycin C to prevent recurrence of pterygium after excision. Ophthalmol 105:1998

162. Hayasaka S, Iwasa Y, Nagaki Y, et al: Late complications after pterygium excision with high dose mitomycin C instillation. Br J Ophthalmol 84:1081, 2000

163. Safianik B, Ben-Zion I, Garzozi HJ: Serious corneoscleral complications after pterygium excision with mitomycin C. Br J Ophthalmol 86:357, 2002

164. Frucht-Pery J, Sugar J, Baum J, et al: Mitomycin C treatment for conjunctival–corneal intraepithelial neoplasia. Ophthalmology 104:2085, 1997

165. Wilson W, Hungerford JL, George SM, et al: Topical mitomycin C for the treatment of conjunctival and corneal epithelial dysplasia and neoplasia. Am J Ophthalmol 124:303, 1997

166. Shields CL, Naseripour M, Shields JA: Topical mitomycin C for extensive, recurrent conjunctival-corneal squamous cell carcinma. Am J Ophthalmol 133:601, 2002

167. Frucht-Pery J, Rozenman Y, Pe'er J: Topical mitomycin C for partially excised conjunctival squamous cell carcinma. Ophthalmology 109:548, 2002

168. Frucht-Pery J, Pe'er J: Use of mitomycin C in the treatment of conjunctival primary acquired melanosis with atypia. Arch Ophthalmol 114:1261, 1996

169. Finger PT, Czechonska G, Liarikos S: Topical mitomycin C chemotherapy for conjunctival melanoma and PAM with atypia. Br J Ophthalmol 82:476, 1998

170. Demirci H, McCormick SA, Finger PT: Topical mitomycin chemotherapy for conjunctival maglignant melanoma and primary acquired melanosis with atypia. Arch Ophthalmol 118:885, 2000

171. Salomao DR, Mathers WD, Sutphin JE, et al: Cytologic changes in the conjunctiva mimicking malignancy after topical mitomycin C chemotherapy. Ophthalmology 106:1756, 1999

172. Liao SL, Kao SCS, Tseng JHS, et al: Results of intraoperative mitomycin C application in dacryocystorhinostomy. Br J Ophthalmol 84:903, 2000

173. Tasi C-C, Kau H-C, Kao S-C, et al: Efficacy of probing the nasolacrimal duct with adjunctive mitomycin C for epiphora in adults. Ophthalmology 109:172, 2002

174. Majmudar PA, Forstot SL, Dennis RF, et al: Topical mitomycin-C for subepithelial fibrosis after refractive corneal surgery. Ophthalmology 107:89, 2000

175. Donnenfeld ED, Perry HD, Wallerstein A, et al: Subconjunctival mitomycin-C for the trteatment of ocular cicatricial pemphigoid. Ophthalmology 106:72, 1999

176. Secchi AG, Tognon MS: Intraoperative mitomycin C in the treatment of cicatricial obliterations of conjunctival fornices. Am J Ophthalmol 122:728, 1996

177. Occleston NI, Daniels JT, Tarnuzzer RW, et al: Single exposures to antiproliferatives. Invest Ophthalmol Vis Sci 38:1998, 1997

178. Kim YY, Sexton RM, Shin DH, et al: Outcomes of primary phakic trabeclectomies without versus with 0.5 to 1 minute versus 3 to 5 minute mitomycin C. Am J Ophhtalmol 126:755, 1998

179. Megevand GS, Salmon JF, Scholtz RP, et al: The effect of reducing the exposure time of mitomycin C in glaucoma filtering surgery. 102:84, 1995

180. Scott IU, Greenfield DS, Schiffman J: Outcomes of primary trabeculectomy with the use of adjunctive mitomycin. Arch Ophthalmol 116:286, 1998

181. Dreyer EB, Chaturvedi N, Zurakowski D: Effect of mitomycin C and fluorouracil – supplemented trebeculectomies in the anterior segment. Arch Ophthalmol 113:578, 1995

182. Robin AL, Ramakrishnan R, Krishnadas R: A long-term dose-response study of mitomycin in glaucoma filtration surgery. Arch Ophthalmol 115:969, 1997

183. Bindlish R, Condon GP, Schlosser JD, et al: Efficacy and safety of mitomycin C in primary trabeculectomy. Ophthalmology 109:1336, 2002

184. Vass C, Georgopoulos M, EL Menyaw I, et al: Intrascleral concentration vs depth profile of mitomycin-C after episcleral application: impact of irrigation. Exp Eye Res 70:139, 2000

185. Mietz H, Jacobi PC, Krieglstein GK: Postoperative application of mitomycin for trabeculectomies. Arch Ophthalmol 118:1341, 2000

186. Mietz H, Jacobi PC, Krieglstein GK: Intra-operative episcleral versus post-operative topical application of mitomycin C for trabeculectomies. Ophthalmology 109:1343, 2002

187. Cohen JS, Greff LJ, Novack GD, et al: A placebo-controlled, double-masked evaluation of mitomycin C in combined glaucoma and cataract procedures. Ophthalmology 103:1934, 1996

188. Carlson DW, Alward WLM, Barad JP, et al: A randomized study of mitomycin augmentation in combined phacoemulsification and trabeculectomy. Ophthalmology 104:719, 1997

189. Shin DH, Simone PA, Song MS, et al: Adjunctive subconjunctival mitomycin C in glaucoma triple procedure. Ophthalmology 102:1550, 1995

190. Shin DH, Kim YY, Ren J, et al: Decrease of capsular opacification with adjunctive mitomycin C in combined glaucoma and cataract surgery. Ophthalmology 105: 1222, 1998

191. Lamping KA, Belkin JK: 5-fluorouracil and mitomycin C in pseudophakic patients. Ophthalmology 102:70, 1995

192. Wu Dunn D, Alfonso E, Palmberg PF: Combined penetrating keratoplasty and trabeculectomy with mitomycin C. Ophthalmology 106:396, 1999

193. Membrey WL, Bruce C, Poinoosawmy DP, et al: Glaucoma surgery with or without adjunctive antiproliferatives in normal tension glaucoma: 2. Visual field progression. Br J Ophthalmol 85:696, 2001

194. Sidoti PA, Belmonte SJ, Liebmann JM, et al: Trabeculectomy with mitomycin C in the treatment of pediatric glaucomas. Ophthalmology 107:422, 2000

195. Beck AD, Wilson WR, Lynch MG, et al: Trabeculectomy with adjunctive mitomycin C in pediatric glaucoma. Am J Ophthalmol 126:648, 1998

196. Manners T, Salmon JF, Barron A, et al: Trabeculectomy with mitomycin C in the treatment of post-traumatic angle recession glaucoma. Br J Ophthalmol 85:159, 2001

197. Lanzl IM, Wilson RP Dudley D, et al: Outcome of trabeculectomy with mitomycin C in the iridocorneal endothelial syndrome. Ophthalmology 107:295, 2000

198. Perkins TW, Cardakli F, Eisele JR, et al: Adjunctive mitomycin C in Molteno implant surgery. Ophthalmology 102:91, 1995

199. Lee D, Shin DH, Birt CM, et al: The effect of adjunctive mitomycin C in Molteno implant surgery. Ophthalmology 104:2126, 1997

200. Spoor TC, McHenry JG, Shin DH: Long-term results using adjunctive mitomycin C in optic nerve sheath decompression for pseudotumor cerebri. Ophthalmology 102:2024, 1995

201. Wenger RM: Synthesis of cyclosporine and analogues: Structural requirements for immunosuppressive activity. Angew Chem Int Ed Engl 24:77, 1985

202. Grevel J, Nuesch E, Abisch E, Kutz K: Pharmacokinetics of oral cyclosporin-A (Sandimmun) in healthy subjects. Eur J Clin Pharmacol 31:211, 1986

203. Vonderscher J, Meinzer A: Rationale for the development of Sandimmune Neoral. Transplant Proc 26:2925, 1994

204. Stephan AG, Barbari A, Masri MA, et al: Evaluation of the new cyclosporine formulation, Consupren, in renal transplant patients. Transplant Proc 28:1348, 1996

205. Mochizuki M, Masuda K, Sakane T: A clinical trial of FK506 in refractory uveitis. Am J Ophthalmol 115:763, 1993

206. Nussenblatt RB, de Smet MD, Rubin B, et al: A masked, randomized dose-response study between cyclosporine A and G in the treatment of sight-threatening uveitis of noninfections origin. Am J Ophthalmol 115:583, 1993

207. Ososz CG, Fidelus RK, Roopenian DC, et al: A new immunosuppressive mechanism for cyclosporin-A demonstrated with cloned T-lymphocytes. Transplant Proc 15:1927, 1983

208. Elliott JF, Lin Y, Mizel SB, et al: Induction of interleukin 2 messenger RNA inhibited by cyclosporin-A. Science 226:1439, 1984

209. Emmel EA, Verweij CL, Durand DB, et al: Cyclosporin-A specifically inhibits function of nuclear proteins involved in T-cell activation. Science 246:1617, 1989

210. Neild GH, Rocchi G, Imberti L, et al: Effect of cyclosporin-A on prostacyclin synthesis by vascular tissue. Thromb Res 32:373, 1983

211. Hiestand PC, Mekler P, Nordmann R, et al: Prolactin as a modulator of lymphocytic responsiveness provides a possible mechanism of action for cyclosporine. Proc Natl Acad Sci USA 83:2599, 1986

212. Burke JF, Pirsch JD, Ramos EL, et al: Long-term efficacy and safety of cyclosporine in renal-transplant recipients. N Engl J Med 331:358, 1994

213. Starzl TE, Porter KA, Iwatsuki S, et al: Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporinsteroid therapy. Lancet 1:583, 1984

214. Beveridge T, Krupp P, McKibbin C: Lymphomas and lymphoproliferative lesions developing under cyclosporine therapy. Lancet 1:788, 1984

215. Diaz-Llopis M, Menezo JL: Penetration of 2% cyclosporine eyedrops into human aqueous humor. Br J Ophthalmol 73:600, 1989

216. Althaus C, Dagres E, Reinhard T: Ciclosporin-A and its metabolites in the anterior chamber after topical and systemic application as determined with high performance liquid chromatography-electrospray mass spectrometry. German J Ophthalmol 5:189, 1996

217. Hunter PA, Wilhelmus KR, Rice NSC, Jones BR: Cyclosporin-A applied topically to the recipient eye inhibits corneal graft rejection. Clin Exp Immunol 45:173, 1981

218. Hunter PA, Garner A, Wilhelmus KR, et al: Corneal graft injection: A new rabbit model and cyclosporin-A. Br J Ophthalmol 66:292, 1982

219. Kana JS, Hoffmann FH, Buchen R, et al: Rabbit corneal allograft survival following topical administration of cyclosporin-A. Invest Ophthalmol Vis Sci 22:686, 1982

220. Newton C, Gebhardt BM, Kaufman HE: Topically applied cyclosporine in azone prolongs corneal allograft survival. Invest Ophthalmol Vis Sci 29:208, 1988

221. Chen YF, Gebhardt BM, Reidy JJ, Kaufman HE: Cyclosporine-containing collagen shields suppress corneal allograft rejection. Am J Ophthalmol 109:132, 1990

222. Salisbury JD, Gebhardt BM: Suppression of corneal allograft rejection by cyclosporin-A. Arch Ophthalmol 99:1640, 1981

223. Coster DJ, Shepherd WFI, Fook TC, et al: Prolonged survival of corneal allografts in rabbits treated with cyclosporin A. Lancet 2:688, 1979

224. Shepherd WFI, Coster DJ, Fook TC, et al: Effect of cyclosporin-A on the survival of corneal grafts in rabbits. Br J Ophthalmol 64:148, 1980

225. Bell TAG, Easty DL, McCallagh KG: A placebo-controlled blind trial of cyclosporin-A in prevention of corneal graft rejection in rabbits. Br J Ophthalmol 66:303, 1982

226. Belin MW, Bouchard CS, Frantz S, Chmielinska J: Topical cyclosporine in high-risk corneal transplants. Ophthalmology 96:1144, 1989

227. Zhao J-C, Jin X-Y: Local therapy of corneal allograft rejection with cyclosporine. Am J Ophthalmol 119:189, 1985

228. Hill JC: The use of cyclosporine in high-risk keratoplasty. Am J Ophthalmol 107:506, 1989

229. Ilari L, Daya SM: Long-term outcomes of keratolimbal allograft for the, treatment of severe ocular surface disorders. Ophthalmology 109:1278, 2002

230. Hill JC: Systemic cyclosporine in high-risk keratoplasty. Short versus long-term therapy. Ophthalmology 101:128, 1994

231. Poon AC, Forbes JE, Dart JKG, et al: Systemic cyclosporin A in high risk penetrating kerotoplasties: a case-controlled study. Br J Ophthalmol 85:1464, 2001

232. Rumelt S, Bersudsky V, Blum-Hareuventi T, et al: Systemic cyclosporin A in high failure risk, repeated corneal transplantation. Br J Ophthalmol 86:988, 2002

233. Hill JC, Potter P: Treatment of Mooren's ulcer with cyclosporin-A: Report of three cases. Br J Ophthalmol 71:11, 1987

234. Wakefield D, Robinson LP: Cyclosporine therapy in Mooren's ulcer. Br J Ophthalmol 74:415, 1987

235. Kruit PJ, Van Balen ATM, Stilma JS: Cyclosporin-A treatment in two cases of corneal peripheral melting syndrome. Doc Ophthalmol 59:33, 1985

236. Kruit PJ: Cyclosporin-A treatment in four cases with corneal melting syndrome. Transplant Proc 20:170, 1988

237. McCarthy JM, Dubord PJ, Chalmers A, et al: Cyclosporine A for the treatment of necrotizing scleritis and corneal melting in patients with rheumatoid arthritis. J Rheumatol 19:1358, 1992

238. Kervick GN, Relugfelder SC, Haimovici R, et al: Paracentral rheumatoid corneal ulceration: Clinical features and cyclosporine therapy. Ophthalmology 99: 80, 1992

239. Hingorani M, Calder VL, Buckley RJ, et al: The immunomodulatory effect of topical cyclosporin A in atopic keratoconjunctivitis. Inves Ophthallmol Vis Sc 40:392, 1999

240. Holland EJ, Chan CC, Kuwabara T, et al: Immunohistologic findings and results of treatment with cyclosporine in ligneous conjunctivitis. Am J Ophthalmol 107:160, 1989

241. BenEzra D, Pe'er J, Brodsky M, Cohen E: Cyclosporine eyedrops for the treatment of severe vernal keratoconjunctivitis. Am J Ophthalmol 101:278, 1986

242. Drosos AA, Skopouli FN, Costopoulos JS, et al: Cyclosporin-A (Cy A) in primary Sjogren's syndrome. Ann Rheum Dis 45:732, 1986

243. Stevenson D, Tauber J, Reis BL, et al: Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease. Ophthalmology 107:967, 2000

244. Kunert KS, Tisdale AS, Gipson IK: Goblet cell numbers and epithelial proliferation in the conjunctiva of patients with dry eye syndrome treated with cyclosporine. Arch Ophthalmol 120:330, 2002

245. Palmer SL, Bowen PA, Green K: Longitudinal tear study after cyclosporine in kidney transplant recipients. Ophthalmology 103:670, 1996

246. Sall K, Stevenson OD, Mundorf TK, et al: Two multicenter randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe eye disease. Ophthalmology 107:631, 2000

247. Small DS, Acheampong A, Reis B, et al: Blood concentrations of cyclosporin A during long-term treatment with cyclosporin A ophthalmic emulsion in patients with moderate to severe dry eye disease. J Ocular Pharmacol Therap 18:411, 2002

248. Nussenblatt RB, Rodriguez MM, Salinas-Carmona MC, et al: Modulation of experimental autoimmune uveitis with cyclosporine-A. Arch Ophthalmol 100:1146, 1982

249. Oh JO, Minasi P, Grabner G, Ohashi Y: Suppression of secondary herpes simplex uveitis by cyclosporine. Invest Ophthalmol Vis Sci 26:494, 1985

250. Mochizuki M, Nussenblatt RB, Kuwabara T, Gery I: Effects of cyclosporine and other immunosuppressive drugs on experimental autoimmune uveoretinitis in rats. Invest Ophthalmol Vis Sci 26:226, 1985

251. Striph G, Doft B, Rabin B, Johnson B: Retina S antigen-induced uveitis: The efficacy of cyclosporine and corticosteroids in treatment. Arch Ophthalmol 104:114, 1986

252. Nussenblatt RB, Dinning WJ, Fujikawa LS, et al: Local cyclosporine therapy for experimental autoimmune uveitis in rats. Arch Ophthalmol 103:1559, 1985

253. Palestine AG, Nussenblatt RB, Chan CC: Cyclosporine penetration into the anterior chamber and spinal fluid. Am J Ophthalmol 99:210, 1985

254. Nussenblatt RB, Rook AH, Wacker WB, et al: Treatment of intraocular inflammatory disease with cyclosporin-A. Lancet 2:235, 1983

255. Nussenblatt RB, Palestine AG, Chan CC: Cyclosporin-A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol 96:275, 1983

256. Bielory L, Holland C, Gascon P, Frohman L: Uveitis, cutaneous and neurosarcoid: Treatment with low-dose cyclosporin-A. Transplant Proc 20(Suppl 4):136, 1988

257. BenEzra D, Cohen E, Chajek T, et al: Evaluation of conventional therapy versus cyclosporine-A in Behçet's syndrome. Transplant Proc 20(Suppl 4):122, 1988

258. BenEzra D, Cohen E, Rakotomalala M, et al: Treatment of endogenous uveitis with cyclosporine-A. Transplant Proc 20(Suppl 4):122, 1988

259. Le Hong P, Girard B, Deray G, et al: Cyclosporine in the treatment of birdshot retinochoroidopathy. Transplant Proc 20(Suppl 4):128, 1988

260. Nussenblatt RB, Palestine AG, Chan CC, et al: Improvement of uveitis and optic nerve disease by cyclosporine in a patient with multiple sclerosis. Am J Ophthalmol 97:790, 1984

261. Rocha G, Deschenes J, Cantarovich M: Cyclosporine monitoring with levels 6 hours after the morning dose in patients with noninfection uveitis. Ophthalmol 104:248, 1997

262. Diaz-Llopis M, Menezo JL: Idiopathic inflammatory orbital pseudotumor and low-dose cyclosporine. Am J Ophthalmol 107:547, 1989

263. Weetman PA, Ludgate M, Mills PV, et al: Cyclosporin improves Graves' ophthalmopathy. Lancet 2:486, 1983

264. Kahaly G, Schrezenmeir J, Schweikert B, et al: Remission—maintaining effect of cyclosporine in endocrine ophthalmopathy. Transplant Proc 18:844, 1986

265. Kahaly G, Schrezenmeir J, Krause U, et al: Cyclosporin and prednisone v. prednisone in treatment of Graves' ophthalmopathy: A controlled randomized and prospective study. Eur J Clin Invest 16:415, 1986

266. Utech C, Wulle KG, Panitz N, Kiefer H: Immunosuppressive treatment of Graves' ophthalmopathy with cyclosporine-A. Transplant Proc 20(Suppl 4):173, 1988

267. Brabant G, Peter H, Becker H, et al: Cyclosporin in infiltrative eye disease. Lancet 1:151, 1984

268. Howlett TA, Lawton NF, Fells P, Besser GM: Deterioration of severe Graves' ophthalmopathy during cyclo-sporin treatment. Lancet 2:1101, 1984

269. McGregor AM, Beck L, Hall R: Cyclosporin-A in management of Graves' disease. J R Soc Med 78:511, 1985

270. Wechsler B, Mertani EB, le Hoang P, et al: Cyclosporine-A is effective, but not safe in the treatment of Behçet's disease. Arthritis Rheum 29:574, 1986

271. Palestine AG, Nussenblatt RB, Chan CC: Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med 77:652, 1984

272. Deray G, Le Hoang P, Cacoub P, et al: Renal function and blood pressure in patients treated with cyclosporin-A for uveitis. Eur J Clin Pharmacol 34:601, 1988

273. Palestine AG, Austin HA, Balow JE, et al: Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J Med 314:1293, 1986

274. Noll RB, Kulkarni R: Complex visual hallucinations and cyclosporine. Arch Neurol 41:329, 1984

275. Rubin AM, Kang H: Cerebral blindness and encephalopathy with cyclosporin-A toxicity. Neurology 37:1072, 1987

276. Rubin AM: Transient cortical blindness and occipital seizures with cyclosporine toxicity. Transplantation 47:572, 1989

277. Avery R, Jabs DA, Wingard JR, et al: Optic disc edema after bone marrow ransplantation. Possible role of cytosporine toxicity. Ophthalmology, 98:1294, 1991

278. Atkinson K: Chronic graft-versus-host-disease. Bone Marrow Transplant 5:69, 1990

279. Jabs DA, Wingard J, Green WR, et al: The eye in bone marrow transplant. Arch Ophthalmol 107:1343, 1989

280. Rikkers SM, Holland GN, Drayton GE, et al: Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol 135:297, 2003

281. Sloper CML, Powell RJ, Dua HS: Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts. Ophthalmology 108:1838, 2001

282. Ogawa 246Y, Okamoto S, Kuwana M, et al: Successful treatment of dry eye in two patients with chronic graft-versus-host disease with systemic administration of FK506 and corticosteroids. Cornea 20:430, 2001

283. Sloper CML, Powell RJ, Dua HS: Tacrolimus (FK506) in the treatment of posterior uveitis refractory to cyclosporine. Ophthalmology 106:723, 1999

284. Shields CL, Honavar SG, Meadows AT, et al: Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol 120:1653, 2002

285. Rogers RS, Seehafer JR, Perry HO: Treatment of cicatricial (benign mucous membrane) pemphigoid with dapsone. J Am Acad Dermatol 6:215, 1982

286. Doan S, Lerovic J-F, Robin H, et al: Treatment of ocular cicatricial pemphigoid with sulfasalazine. Ophthalmology 108:1565, 2001

287. Elder MJ, Leonard J, Dart JKG: Sulphapyridine—a new agent for the treatment of ocular cicatricial pemphigoid. Br J Ophthalmol 80:549, 1996

288. Jacobs LD, Beck RW, Simon JH, et al: Intramuscular interferon beta–1a therapy initiated during a first demyelinating event in multiple sclerosis. N Engl J Med 343:898, 2000

289. CHAMPS Study Group: Interferon ?–1a for optic neuritis patients at high risk for multiple sclerosis. Am J Ophthalmol 132:463, 2001

290. Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis: Defining the clinical course of multiple sclerosis. Neurology 46:907, 1996

291. Study Group and University British Columbia MS/MRI Analogs Group: Prisms –4: Long term efficacy of interferon-?–1a in relapsing MS. Neurology 56:1628, 2001

292. SPECTRIMS Study Group: randomized controlled trial of interferon beta–1a in secondary progressive MS. Neurology 56:1496, 2001

293. Adams CP Jr , Cohen EJ, Albrecht J, et al: Interferon treatment of adenoviral conjunctivitis. Am J Ophthalmol 98:429, 1984

294. Blasi MA, Gherlinzoni F, Calvisi G, et al: Local chemotherapy with interferon-? for conjunctival mucosa-associated lymphoid tissue lymphoma. Ophthalmology 108:559, 2001

295. Vann RR, Karp CL: Perilesional and topical interferon alpha–2b for conjunctival and corneal neoplasia. Ophthalmology 106:91, 1999

296. Schechter BA, Rand WJ, Velazquez GE, et al: Treatment of conjunctival papillomata with topical interferon alpha–2b. Am J Ophthalmol 134:268, 2002

297. Moazami G, Auran JD, Florakis GJ: Interferon treatment of Mooren's ulcers associated with hepatitis C. Am J Ophthalmol 119:365, 1995

298. Ikeda T, Sato K, Tokuyama T: Interferon alfa therapy against metastatic iris tumor of renal cell carcinoma. Arch Ophthalmol 118:846, 2000

299. Loughnan JS, Elder J, Kemp A: Treatment of a massive orbital-capillary hemangioma with interferon alpha–2b, short-term results. Arch Ophthalmol 110:1366, 1992

300. Poliner LS, Tornambe PE, Mickelson PE: Interferon alpha–2a for subfoveal neovascularization in age-related macular degeneration. Ophthalmol 100:1417, 1993

301. Kirkpatrick JNP, Dick AD, Forrester JV: Clinical experience with interferon alpha–2a for exudative age-related macular degeneration. Br J Ophthalmol 77:766, 1993

302. Chan CK, Kempin SJ, Noble SK: The treatment of choroidal neovascular membranes by alpha interferon. Ophthalmology 101:289, 1994

303. Thomas MA, Ibanez HE: Interferon alfa–2a in the treatment of subfoveal choroidal neovascularization. Am J Ophthalmol 115:563, 1993

304. Ross C, Engler CB, Sander B: IFN-? antibodies in patients with age-related macular degeneration treated with recombinant human IFN-? 2a. J Interferon Cytokine Res 22:421, 2002

305. Larkin G, Lightman S: Mycophenotate mofetil, a useful immunosuppressive in inflammatory eye disease. Ophthalmology 106:370, 1999

306. Kilmartin DJ, Forrester JV, Dick AD: Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet 352:35, 1998

307. Reis A, Reinhard T, Voiculescu A: Mycophenolate mofetil versus cyclosporin A in high risk keratoplasty patients: a prospectively randomized clinical trial. Br J Ophthalmol 83:1268, 1999

308. Foster CS, Tufail F, Waheed NK, et al: Efficacy fo etanercept in preventing relapse of uveitis controlled by methrotrexate. Arch Ophthalmol 121:437, 2003

309. El-Shabrawi Y, Hermann J: Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27-associated acute anterior uveitis. Ophthalmology 109:2342, 2002

310. Triolo G, Accardo-Palumbo A, Ferrante A, et al: Anti-tumor necrosis factor monoclonal antibody treatment for ocular Behcet's disease. Ann Rheum Dis 61:560, 2002

Back to Top